<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        78-249-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ANASTRALEX 1 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ANASTROZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        128.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Apotex Inc. (Garyray) " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Apotex Inc. (Garyray) 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX INC. (SIGNET SITE)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG03 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What is ANASTRALEX:</strong></p><p>ANASTRALEX is used for the treatment of postmenopausal women with hormone receptor positive breast cancer in the following conditions:</p><ul><li>adjuvant treatment for early breast cancer</li><li>advanced breast cancer</li></ul><p>&nbsp;</p><p><strong>What it does:</strong></p><p>In hormone sensitive breast cancer, estrogens fuel tumour growth. Following menopause, estrogens are still produced in small amounts in other tissues of the body such as the breasts, muscle and fat. These estrogens are produced when androgens (hormones produced by the adrenal glands) interact with aromatase, a naturally occurring enzyme in the body.</p><p>ANASTRALEX belongs to a group of medicines called aromatase inhibitors and works by inhibiting the aromatase enzyme, thereby, suppressing the production of estrogens that can stimulate tumour growth. Suppressing the production of estrogens may help reduce the growth of breast cancer and delay the breast cancer from recurring.</p><p>Adjuvant means &quot;in addition to.&quot; In early breast cancer, this means that additional treatment is required after primary treatment. The reason for this is that after surgery, a small number of cancer cells may remain in the body. These cells can continue to multiply and spread. Adjuvant therapy is given to prevent or delay these cells from multiplying and spreading. The purpose of adjuvant therapy with ANASTRALEX is to help to delay the breast cancer from recurring. Cytotoxic chemotherapy, radiation, and hormonal treatment are three common forms of adjuvant treatment.</p><p>&nbsp;</p><p><strong>When it should not be used:</strong></p><ul><li>If you are allergic to the active ingredient Anastrozole or any nonmedicinal ingredients of ANASTRALEX. If you think you may be allergic, ask your doctor for advice.</li><li>If you are pregnant or breast-feeding.</li></ul><p>&nbsp;</p><p><strong>What dosage forms it comes in:</strong></p><p>Each ANASTRALEX tablet contains 1 milligram of Anastrozole.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:center"><strong>Serious Warnings and Precautions</strong></p><ul><li><strong>ANASTRALEXE should not be given to premenopausal women.</strong></li><li><strong>ANASTRALEXE should not be given to children.&nbsp;</strong></li><li><strong>Patients with liver and/or kidney problems and patients with osteoporosis or at risk for osteoporosis should be carefully monitored by the doctor.</strong></li><li><strong>ANASTRALEXE should be prescribed by a doctor experienced in the use of anti-cancer drugs</strong></li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>Before starting ANASTRALEX and to get the best possible treatment, be sure to tell your doctor if you:</strong></p><ul><li>If you have any disorder or disease which affects your heart, liver or kidneys.</li><li>ANASTRALEX lowers the level of female hormones and this may lead to a loss of mineral content of bones, which might decrease their strength and lead to a broken bone. You should talk to your doctor about your osteoporosis risk before using ANASTRALEX.</li></ul><p>ANASTRALEX tablets are unlikely to affect your ability to drive a car or to operate machinery.<br />However, some patients may occasionally feel weak or sleepy. If this happens, you should not drive or operate machinery.</p><p>&nbsp;</p><p><strong>BEFORE you use ANASTRALEX talk to your doctor or pharmacist:</strong></p><ul><li>If you take medicine containing estrogen (a female sex hormone). It may oppose the effect of ANASTRALEX. Some herbal products contain estrogen.</li><li>If you are currently taking Tamoxifen.</li><li>If you are taking or have recently taken other medicines, even those not prescribed by a doctor.</li><li>Please note that these statements may also apply to medicine used some time ago.<br />&nbsp;</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u><strong>Usual dose:</strong></u><br />Follow your doctor&rsquo;s instructions about when and how to take your ANASTRALEX tablets. The usual dose is one tablet once a day. Swallow the tablet with fluids. Try to take your tablet at the same time each day.</p><p>For adjuvant treatment of early breast cancer, currently it is recommended that ANASTRALEX be taken for 5 years.</p><p>&nbsp;</p><p><u><strong>Proper Handling Instructions:</strong></u><br />No special instructions for handling are required.</p><p>&nbsp;</p><p><u><strong>Overdose:</strong></u><br />If you take more than your normal dose of ANASTRALEX, contact your doctor, pharmacist, regional poison control center or nearest hospital.</p><p>&nbsp;</p><p><u><strong>Missed Dose:</strong></u><br />Take the last missed dose as soon as you remember, as long as it is at least 12 hours before the next dose is due.</p><p>If it is less than 12 hours to the next dose, do not take the dose you have missed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ANASTRALEX can have side effects.</p><p>Contact your doctor immediately if any of the following happens to you. You may need further examinations or treatment:</p><ul><li>Severe skin reactions (Stevens-Johnson syndrome) with lesions, ulcers or blisters. This type of skin reaction is very rare.</li><li>Allergic reaction with swelling of the face, lips, tongue and/or throat which may cause difficulty in swallowing and/or breathing.</li><li>Chest pain or angina, as a result of ischemic heart disease (reduced blood flow in the vessels of the heart).</li><li>Inflammation of the liver (hepatitis). Symptoms may include a general feeling of being unwell, with or without jaundice (yellowing of the skin and eyes) and pain in the upper abdomen on the right side.</li><li>If you experience nausea, vomiting and thirst, you should tell your doctor. These symptoms may indicate possible increased blood calcium levels.</li></ul><table border="1" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center"><strong>SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM</strong></p></td></tr><tr><td><p><strong>Symptom / effect</strong></p></td><td><p><strong>Talk with your doctor or pharmacist</strong></p></td><td><p><strong>Seek immediate emergency medical assistance</strong></p></td></tr><tr><td colspan="3"><p><strong>Very common (greater than or equal to 10 of every 100 patients are likely to have these events)</strong></p></td></tr><tr><td><p>Hot flushes</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Joint pain, joint stiffness or broken bones</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><strong>Common (greater than or equal to 1 of every 100 patients, but less than 10 of every 100 patients, are likely to have these events)</strong></p></td></tr><tr><td><p>Weakness</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Carpal tunnel syndrome (tingling, pain, coldness, weakness in parts of the hand)</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Tickling, tingling or numbness of skin, loss/ lack of taste</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Vaginal dryness</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hair thinning (alopecia)</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diarrhea</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Headache</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Changes in blood tests of liver function</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Bone pain</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Muscle pain</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><strong>Uncommon (greater than or equal to 1 of every 1000 patients, but less than 10 of every 1000 patients, are likely to have these events)</strong></p></td></tr><tr><td><p>Vaginal bleeding</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Loss of appetite</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>High blood cholesterol</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Vomiting</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Sleepiness/tiredness</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Trigger finger</p></td><td><p>✔</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hepatitis</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td colspan="3"><p><strong>Very Rare </strong><strong>(less than 1 of every 10 000 patients are likely to have these events)</strong></p></td></tr><tr><td><p>Severe skin reactions</p></td><td><p>✔</p></td><td><p>✔</p></td></tr><tr><td><p>Allergic reactions</p></td><td><p>✔</p></td><td><p>✔</p></td></tr></tbody></table><p><strong>This is not a complete list of side effects. For any unexpected effects while taking APO-ANASTROZOL contact your doctor or pharmacist</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of reach and sight of children.</li><li>Store below 30&deg;C. Protect from moisture.</li><li>Keep your ANASTRALEX tablets in the original container.</li><li>Do not use ANASTRALEX after the expiry date on the package.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance is Anastrozole.</strong></p><p>Each ANASTRALEX Tablet 1 mg contains 1 mg Anastrozole USP.</p><p><strong>Other ingredients:</strong></p><p>Anhydrous lactose, Croscarmellose sodium, Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, Magnesium stearate, Microcrystalline cellulose, Polyethylene glycol and Titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form
 Tablets – 1 mg

Physical description
White, round, biconvex coated tablet. Engraved "APO" on one side, "AN" over "1" on the other side.

Contents of the pack
Available in bottle of 30 tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Apotex Inc.</p><p>150 Signet Drive</p><p>Toronto, Ontario</p><p>Canada M9L 1T9</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Apotex Inc. (S.P. Facility)</p><p>285 Garyray Drive</p><p>Toronto, Ontario</p><p>Canada M9L 1P3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما المقصود بالدواء أناسترالكس:</strong><br />يُستخدم أناسترالكس لعلاج النساء في مرحلة ما بعد انقطاع الطمث المصابات بسرطان الثدي الإيجابي لمستقبلات الهرمون في الحالات التالية:</p><ul><li>علاج مساعد لسرطان الثدي المبكر</li><li>سرطان الثدي المتقدم</li></ul><p>&nbsp;</p><p><strong>كيفية عمل الدواء:</strong><br />في حالة سرطان الثدي الحساس للهرمون؛ تحفز الإستروجينات نمو الورم. بعد انقطاع دورة الحيض (الطمث)؛ يستمر إنتاج الإستروجينات بكميات صغيرة في أنسجة أخرى من الجسم مثل الثديين والعضلات والدهون. وتُنتج تلك الإستروجينات عندما تتفاعل الإندروجينات (هرمونات تُنتج بواسطة الغدد الكظرية) مع إنزيم أروماتاز وهو إنزيم يُنتج في الجسم بشكل طبيعي.</p><p>ينتمي الدواء أناسترالكس إلى فئة من الأدوية تُسمى مثبطات الأروماتاز، ويعمل الدواء على تثبيط إنزيم الأروماتاز، ومن ثم قمع إنتاج الإستروجينات التي يمكن أن تحفز نمو الورم. ويمكن أن يساعد قمع إنتاج الإستروجينات على تقليل نمو سرطان الثدي وتأخير تكرار حدوث سرطان الثدي.</p><p>يُقصد بعبارة &quot;علاج مساعد&quot; أنه يُستخدم إلى جانب دواء آخر. في حالة سرطان الثدي المبكر؛ يُقصد بهذه العبارة أنه يلزم استخدام إضافي بعد العلاج الأولي. وسبب ذلك أنه بعد إجراء الجراحة؛ قد يتبقى عدد صغير من الخلايا السرطانية في الجسم. ويمكن أن تستمر هذه الخلايا في التكاثر والانتشار. ولذا يُعطى العلاج المساعد لمنع أو لتأخير تكاثر هذه الخلايا وانتشارها. والهدف من العلاج المساعد باستخدام أقراص أناسترالكس هو المساعدة في تأخير تكرار حدوث سرطان الثدي. ويمثل كل من العلاج الكيميائي السام للخلايا والعلاج بالإشعاع والعلاج الهرموني الخيارات الثلاثة الشائعة للعلاج المساعد.</p><p>&nbsp;</p><p><strong>موانع استعمال هذا الدواء:</strong></p><ul><li>في حالة الحساسية تجاه المادة الفعالة &ndash; أناسترازول &ndash; أو أيٍ من المكونات غير الدوائية الأخرى في أقراص أناسترالكس. إذا كنت تعتقدين أنك قد تُصابين بحساسية، فاستشير الطبيب.</li><li>في حالة الحمل أو الرضاعة الطبيعية.</li></ul><p>&nbsp;</p><p><strong>ما أشكال الجرعات التي يتوفر بها هذا الدواء:</strong></p><p>يحتوي كل قرص من أناسترالكس على 1 ملليجرام من أناسترازول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:center"><strong>التحذيرات الخطيرة والاحتياطات</strong></p><ul><li>ينبغي عدم إعطاء أناسترالكس للنساء قبل انقطاع الطمث.</li><li>ينبغي عدم إعطاء أناسترالكس للأطفال.&nbsp;</li><li>ينبغي مراقبة حالة مرضى الكبد و/ أو الكلى ومرضى تخلخل العظام أو المعرضين لتخلخل العظام - بعناية بواسطة الطبيب.</li><li>ينبغي استخدام أناسترالكس تحت إشراف طبيب خبير في استخدام الأدوية المضادة للسرطان.</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>قبل بدء استخدام أقراص أناسترالكس، ولتحقيق أفضل فعالية علاجية ممكنة، يُرجى التأكد من إخبار الطبيب إذا كان أي من الحالات التالية ينطبق عليك:</strong></p><ul><li>وجود أي اضطراب أو مرض يؤثر على القلب أو الكبد أو الكلى.</li><li>يخفض أناسترالكس مستوى هرمونات الأنوثة، وقد يؤدي هذا إلى فقدان نسبة من المعادن في العظام، وقد يترتب على ذلك ضعف العظام وهشاشتها. ينبغي التحدث إلى الطبيب عن احتمال تعرضك للإصابة بتخلخل العظم قبل استخدام أقراص أناسترالكس.</li></ul><p>ليس من المحتمل أن تؤثر أقراص أناسترالكس على القدرة على قيادة المركبات أو تشغيل الآلات.<br />ولكن قد يشعر بعض المرضى بالضعف أو النعاس أحيانًا. إذا حدث ذلك لك؛ فينبغي تجنب قيادة السيارات أو تشغيل آلات.</p><p>&nbsp;</p><p><strong>قبل البدء في استخدام أناسترالكس، ينبغي استشارة الطبيب أو الصيدلي في الحالات التالية:</strong></p><ul><li>في حالة استخدام أدوية محتوية على الإستروجين (هرمون أنثوي). قد يتعارض مفعول تلك الأدوية مع مفعول أناسترالكس. بعض المنتجات العشبية تحتوي على الإستروجين.</li><li>في حالة استخدام العقار تاموكسفين حاليًا.</li><li>في حالة استخدام أدوية أخرى &ndash; حاليًا أو سابقًا - حتى تلك التي تأخذينها بدون وصفة طبية من الطبيب.</li><li>يُرجى ملاحظة أن هذه البيانات يمكن أن تنطبق أيضًا على أدوية سبق استخدامها في الماضي.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>الجرعة العادية:</strong><br />ينبغي اتباع تعليمات الطبيب المعالج بشأن مواعيد وكمية الجرعة المستخدمة من أقراص أناسترالكس. الجرعة العادية هي قرص واحد مرّة واحدة يوميًا. يُبلع القرص مع مقدار من السوائل. احرصي على تناول القرص في وقت واحد محدد كل يوم.<br />بالنسبة إلى العلاج المساعد لسرطان الثدي المبكر؛ يوصى حاليًا باستخدام أقراص أناسترالكس لمدة 5 سنوات.</p><p>&nbsp;</p><p><strong>تعليمات الاستخدام الصحيح:</strong><br />لا توجد تعليمات خاصة للاستخدام.</p><p>&nbsp;</p><p><strong>الجرعة الزائدة:</strong><br />في حالة تناول جرعة زائدة عن الجرعة العادية من أناسترالكس؛ ينبغي الاتصال بالطبيب أو الصيدلي أو مركز مكافحة السموم الإقليمي أو أقرب مستشفى.</p><p>&nbsp;</p><p><strong>الجرعة الفائتة:</strong><br />ينبغي تناول القرص الفائت بمجرد تذكره مادام الوقت المتبقي على الجرعة التالية لا يقل عن 12 ساعة على الأقل.</p><p>ولكن إذا كان الوقت المتبقي على موعد الجرعة التالية أقل من 12 ساعة، فلا تتناولي الجرعة التي نسيتيها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن أن يسبب تناول أقراص أناسترالكس حدوث آثار جانبية.<br />ينبغي الاتصال بالطبيب فورًا إذا حدث أي من الأعراض التالية لديك: وذلك لأنك قد تحتاجين إلى مزيد من الفحوص والعلاج:</p><ul><li>تفاعلات جلدية شديدة (متلازمة ستيفن جونسون) مع آفات أو قروح أو تنفطات. هذا النوع من التفاعل الجلدي نادر الحدوث جدًا.</li><li>تفاعل تحسسي مع تورم الوجه والشفتين واللسان و/أو الحلق مما يؤدي إلى الشعور بصعوبة في البلع و/أو التنفس.</li><li>ألم في الصدر أو ذبحة صدرية نتيجة مرض القلب الإقفاري (نقص تدفق الدم في أوعية القلب).</li><li>التهاب الكبد. يمكن أن تشمل الأعراض شعورًا عامًا بالإعياء مع أو بدون يرقان (اصفرار الجلد والعينين)، وألم في أعلى الجانب الأيمن من البطن.</li><li>اذا شعرت بالغثيان أو العطش أو بدأت بالتقيؤ، ينبغي عليك اخبار طبيبك. هذه الأعراض قد تشير الى زيادة في مستوى الكالسيوم في الدم.</li></ul><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:582px"><tbody><tr><td colspan="3"><p dir="RTL" style="text-align:center"><strong>&nbsp;الآثار الجانبية الخطيرة، ومدى تكرار حدوثها وكيفية التعامل معها</strong></p></td></tr><tr><td><p dir="RTL" style="text-align:center"><strong>العَرض/الأثر</strong></p></td><td><p dir="RTL"><strong>تحدث إلى الطبيب أو الصيدلي</strong></p></td><td><p dir="RTL"><strong>اطلبي الرعاية الطبية الطارئة الفورية</strong></p></td></tr><tr><td colspan="3"><p dir="RTL"><strong>شائعة جدًا (يُحتمل أن يُصاب 10 مريضات أو أكثر بهذه الأعراض من كل 100 مريضة)</strong></p></td></tr><tr><td><p dir="RTL">نوبات توهج</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">ألم في المفاصل، تيبس المفاصل أو انكسار العظم</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td colspan="3"><p dir="RTL"><strong>شائعة (يُحتمل أن تُصاب مريضة واحدة أو أكثر ولكن أقل من 10 بهذه الأعراض من كل 100 مريضة)</strong></p></td></tr><tr><td><p dir="RTL">ضعف</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">متلازمة النفق الرسغي (وخز، ألم، برودة، ضعف في أجزاء من اليد)</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">دغدغة أو وغز أو فقدان الإحساس في الجلد\فقدان أو نقص في التذوق</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">جفاف المهبل</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">نحول الشعر (صلع)</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">طفح جلدي</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">غثيان</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">إسهال</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">صداع</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">تغيرات في نتائج اختبار الدم لوظائف الكبد</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">ألم في العظام</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">ألم في العضل</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td colspan="3"><p dir="RTL"><strong>غير شائعة (يُحتمل أن تُصاب مريضة واحدة أو أكثر ولكن أقل من 10 بهذه الأعراض من كل 1000 مريضة)</strong></p></td></tr><tr><td><p dir="RTL">النزيف المهبلي</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">فقدان الشهية</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">زيادة الكولسترول في الدم</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">قيء</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">نوم/تعب</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">إصبع الزناد</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">التهاب كبدي</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">✔</p></td></tr><tr><td colspan="3"><p dir="RTL"><strong>نادرة جدًا </strong>(يُحتمل أن تُصاب أقل من&nbsp; مريضة واحدة بهذه الأعراض من كل 10000 مريضة)</p></td></tr><tr><td><p dir="RTL">تفاعلات جلدية شديدة</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">✔</p></td></tr><tr><td><p dir="RTL">تفاعلت تحسسية</p></td><td><p dir="RTL">✔</p></td><td><p dir="RTL">✔</p></td></tr></tbody></table><p><strong>وهذه ليست كل الآثار الجانبية. في حالة حدوث أي آثار غير متوقعة أثناء تناول الدواء أناسترالكس، اتصلي بالطبيب أو الصيدلي.</strong><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>يجب حفظه بعيدًا عن متناول الأطفال ونظرهم.</li><li>يخزن في درجة حرارة أقل من 30 درجة مئوية. &nbsp;يٌحفظ بعيداً عن الرطوبة.</li><li>يجب حفظ أقراص أناسترالكس في العبوة الأصلية.</li><li>لا تستخدمي أناسترالكس بعد تاريخ انتهاء الصلاحية المكتوب على العبوة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>المادة النشطة هي أناسترازول.&nbsp;</strong></p><p>يحتوي كل قرص من أناسترالكس على 1 ملجم من أناسترازول (دستور الأدوية الأمريكية).</p><p><strong>المكونات الأخرى&nbsp;</strong></p><p>لاكتوز لامائي، كروسكارميلوز صوديوم، هيدروكسي بروبيل سليولوز، هيدروكسي بروبيل ميثيل سليولوز، ستيرات الماغنيسيوم، سيلولوز دقيق البلورات، بولي إيثيلين جليكول، ثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;الشكل الصيدلاني</strong><br />&nbsp;أقراص &ndash; 1 ملجم</p><p><strong>الوصف المادي</strong><br />أقراص بيضاء، مستديرة، محدّبة الوجهين، مغلفة. منقوش على أحد جانبي كل قرص الأحرف &quot;APO&quot;، وعلى الجانب الآخر منقوش الأحرف &quot;AN&quot; على الرقم &quot;1&quot;.</p><p><strong>محتويات العبوة</strong><br />تتوفر الأقراص في عبوات بكل منها 30 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة صاحبة تفويض التسويق:</strong><br />شركة أبوتكس إنك.<br />150 سيجنت درايف، تورانتو، أونتاريو، كندا، ام 9 ال &nbsp;1تي9&nbsp;</p><p>&nbsp;</p><p><strong>الشركة المصنعة:</strong><br />شركة أبوتكس إنك. (مصنع أس.بي)&nbsp;<br />285 جاريراي درايف، تورانتو، أونتاريو، كندا، ام 9 ال 1پي3</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trade Name in the GCC: Anastralex
Trade Name in Country of Origin: Apo-Anastrozole
Generic Name: Anastrozole
Dosage Form: Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ANASTROZOLE 1 mg Tablets:  Each white, biconvex, film-coated tablet, engraved “APO” on one side and “AN” over “1” on the other side, contains 1 mg of anastrozole.
Available in bottles of 30 tablets.

In addition to the active ingredient, anastrozole, each tablet also contains the non-medicinal ingredients:
Croscarmellose sodium
Hydroxypropyl cellulose
Hydroxypropyl methylcellulose
Magnesium stearate
Microcrystalline cellulose
Polyethylene glycol
Titanium dioxide

For detailed composition, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                APO-ANASTROZOLE 1 mg Tablets:  Each white, biconvex, film-coated tablet, engraved “APO” on one side and “AN” over “1” on the other side, contains 1 mg of anastozole.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>APO-ANASTROZOLE (anastrozole) is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</p><p>Approval is based on superior disease-free survival for anastrozole in comparison to tamoxifen. However, overall survival was not significantly different between the two treatments (see <strong>5.3</strong>).</p><p>APO-ANASTROZOLE (anastrozole) is indicated for hormonal treatment of advanced breast cancer in postmenopausal women.</p><p>&nbsp;</p><p><strong>Geriatrics:</strong></p><p>No changes in dose are necessary for elderly patients.</p><p>&nbsp;</p><p><strong>Pediatrics:</strong></p><p>APO-ANASTROZOLE is not recommended for use in pediatric patients as safety and efficacy have not been established in this group of patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Dosing considerations</u></strong></p><p><strong>Age</strong>: Patients should be postmenopausal.</p><p>&nbsp;</p><p><strong><u>Recommended Dose and Dosage Adjustment</u></strong></p><p>Apo-Anastrozole (anastrozole) should be administered 1 mg orally, once a day.</p><p>In the adjuvant setting, it is currently recommended that treatment be given for 5 years.</p><p><strong>Elderly</strong>: No changes in dose are necessary for elderly patients.</p><p><strong>Hepatic Impairment</strong>: Although the apparent oral clearance of anastrozole was decreased in subjects with cirrhosis due to alcohol abuse, plasma anastrozole concentrations remained within the range seen across all clinical trials in subjects without liver disease. Therefore, no changes in dose are recommended for patients with mild-to-moderate hepatic impairment, although patients should be monitored for side effects. Anastrozole has not been studied in patients with severe hepatic impairment. The potential risk/benefit to such patients should be carefully considered before administration of Anastrozole.</p><p><strong>Renal Impairment</strong>: No changes in dose are necessary for patients with renal impairment. The potential risk/benefit to patients with severe renal impairment should still be considered prior to the administration of anastrozole in these patients.</p><p>&nbsp;</p><p><strong><u>Missed Dose</u></strong></p><p>A missed dose should be taken as soon as possible, as long as it is taken at least 12 hours before the next dose is due. A missed dose should not be taken within 12 hours of the next dose.</p><p>&nbsp;</p><p><strong><u>Administration</u></strong></p><p>Patients should swallow APO-ANASTROZOLE with fluids.</p><p>Patients should try to take APO-ANASTROZOLE at the same time each day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Patients who are hypersensitive to APO-ANASTROZOLE (anastrozole) or to any ingredient in the formulation. For a complete listing, see the Section 2.
• Pregnant or lactating women.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p style="text-align:center"><strong>Serious</strong><strong> Warnings and Precautions&nbsp;</strong></p><ul><li>Not recommended for use in pre-menopausal women as safety and efficacy have not been established in these patients (see <strong>5.4</strong>)</li><li>Not recommended for use in pediatric patients as safety and efficacy have not been established in these patients (see Special Populations, Pediatrics section below).</li><li>Potential risk/benefit should be carefully assessed in patients with severe hepatic and severe renal impairment (see Hepatic/Biliary and Renal sections below).</li><li>Potential risk/benefit should be carefully assessed in patients with osteoporosis or risk factors for osteoporosis (see Musculoskeletal section below).</li><li>hould be administered under the supervision of a qualified physician experienced in the use of anti-cancer agents (see <strong>4.2</strong>).</li></ul></td></tr></tbody></table><p><strong><u>Body as a Whole</u></strong></p><p>Anastrozole is unlikely to impair the ability of patients to drive and operate machinery. However, asthenia and somnolence have been reported with the use of anastrozole and caution should be observed when driving or operating machinery while such symptoms persist.</p><p>&nbsp;</p><p><strong><u>Cardiovascular</u></strong></p><p>In the ATAC trial, ischemic cardiovascular events were reported more frequently in patients treated with anastrozole compared to those treated with tamoxifen, although the difference was not statistically significant. A retrospective evaluation has shown that this numerical difference was associated with a sub-group of patients with pre-existing ischemic heart disease. A statistical analysis could not be performed on this subgroup evaluation. Serious adverse events continued to be collected during the off-treatment follow-up and the incidence of cardiovascular events reported was similar in the anastrozole and tamoxifen arms (3.9% vs. 3.7%, respectively).</p><p>&nbsp;</p><p><strong><u>Hepatic/Biliary</u></strong></p><p>Anastrozole pharmacokinetics have been investigated in subjects with stable hepatic cirrhosis related to alcohol abuse. The apparent oral clearance of anastrozole was approximately 30% lower in subjects with hepatic cirrhosis than in control subjects with normal liver function.</p><p>However, plasma anastrozole concentrations in the subjects with hepatic cirrhosis are within the range of concentrations seen in normal subjects across all clinical trials. Dosage adjustment</p><p>in patients with mild-to-moderate hepatic dysfunction is not necessary. Anastrozole has not been investigated in patients with severe hepatic impairment. The potential risk/benefit to such patients should be carefully considered before administration of anastrozole.</p><p>&nbsp;</p><p><strong><u>Musculoskeletal</u></strong></p><p><strong>Bone Mineral Density</strong>: The use of estrogen lowering agents, including anastrozole, may cause a reduction in bone mineral density with a possible consequent increased risk of fracture. Data available from a phase III/IV study [SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE)] showed that in postmenopausal women with hormone receptor positive early breast cancer with existing moderate (T-score &lt; &ndash;1.0 in either lumbar spine or total hip, provided neither of these was less than &ndash;2.0, and with no personal history of a fragility fracture) or high risk (Tscore &lt; -2.0 in either the lumbar spine, or hip, or a personal history of fragility fracture) of fragility fracture, bone mineral density (BMD) loss could be inhibited by using anastrozole together with a bisphosphonate (risedronate). All patients in the study received vitamin D and calcium supplementation. Patients at existing low risk (T-score in both the lumbar spine, and total hip, of -1.0 or higher, and no personal history of fragility fracture) of fragility fracture in the study were treated with anastrozole only and did not have a loss of lumbar spine BMD following 12 months of treatment although statistically significant changes were seen following 24 months of treatment (estimated percentage change &ndash;2.07%; 95% Confidence Interval: -3.60, -0.53; p=0.0109). No change in total hip BMD was seen at 12 and 24 months in the low-risk group (see Clinical Trials, Adjuvant treatment of breast cancer in postmenopausal women &ndash; assessment of bone). Women should have their osteoporosis risk assessed and managed according to local clinical practice and guidelines.</p><p><strong>Myalgia</strong>: Myalgia has been associated with both anti-estrogens and estrogen-lowering agents. In the adjuvant setting, muscle pain was reported in the ATAC study at a higher incidence for Anastrozole (5.8%) compared to tamoxifen (5.2%).</p><p>&nbsp;</p><p><strong><u>Other</u></strong></p><p>Anastrozole has not been investigated in patients with any degree of brain or leptomeningeal involvement or with pulmonary lymphangitic disseminated disease.</p><p>&nbsp;</p><p><strong><u>Renal</u></strong></p><p>Anastrozole pharmacokinetics have been investigated in subjects with renal insufficiency. Anastrozole renal clearance decreased proportionately with creatinine clearance and was approximately 50% lower in subjects with severe renal impairment (creatinine clearance less than 30 mL/min/1.73m2&nbsp;or 0.5 mL/sec/1.73m2) compared to controls. Because renal clearance is not a significant pathway of elimination, the apparent oral clearance of anastrozole is unchanged even in severe renal impairment. Dosage adjustment in patients with renal dysfunction is not necessary.</p><p>Anastrozole has not been investigated in patients with breast cancer and severe renal impairment. The potential risk/benefit to patients with severe renal impairment should be carefully considered prior to the administration of anastrozole.</p><p>&nbsp;</p><p><strong><u>Special Populations</u></strong></p><p><strong>Pregnant</strong><strong> Women: </strong>Anastrozole is contraindicated in pregnant women.</p><p>The extent of exposure in pregnancy to anastrozole during clinical trials and postmarketing is very limited to individual cases only. If a patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus or potential risk for loss of the pregnancy.</p><p>Anastrozole has been found to cross the placenta following oral administration of 0.1 mg/kg in rats and rabbits. Studies in both rats and rabbits at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively (about 1 and 1/3, respectively, the recommended human dose on a mg/m2&nbsp;basis), administered during the period of organogenesis showed that anastrozole increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption and decreased numbers of live fetuses). Effects were dose related in rats. Placental weights were significantly increased in rats at doses of 0.1 mg/kg/day or more.</p><p>Evidence of fetotoxicity, including delayed fetal development (i.e. incomplete ossification and depressed fetal body weights), was observed in rats administered doses of 1 mg/kg/day (about 8 times the recommended human dose on a mg/m2 basis). There was no evidence of teratogenicity in rats administered doses up to 1 mg/kg/day. In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1 mg/kg/day (about 16 times the recommended human dose on a mg/m2 basis). There was no evidence of teratogenicity in rabbits administered 0.2 mg/kg/day (about 3 times the recommended human dose on a mg/m2 basis).</p><p>&nbsp;</p><p><strong>Nursing Women: </strong>Anastrozole is contraindicated in lactating women.</p><p><strong>Pediatrics: </strong>Anastrozole is not recommended for use in pediatric patients as safety and efficacy have not been established.</p><p><strong>Geriatrics: </strong>Anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer. The pharmacokinetics were similar in volunteers and in patients, and no age related effects were seen.</p><p>&nbsp;</p><p><strong><u>Monitoring and Laboratory Tests</u></strong></p><p>Anastrozole has not been observed to interfere with routine clinical laboratory test results.</p><p>During the ATAC trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9.0% versus 3.5%, respectively). Lipid profile was assessed as part of the SABRE trial. In this study, treatment for 12 months with anastrozole alone had a neutral effect on lipid profile.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Overview</u></strong></p><p>Anastrozole inhibits reactions catalyzed by cytochrome P450 1A2, 2C8/9, and 3A4 <em>in vitro </em>with Ki values which are approximately 30 times higher than the mean plasma steady-state Cmax values observed following a 1 mg daily dose. Anastrozole has no inhibitory effect on reactions catalyzed by cytochrome P450 2A6 or 2D6 <em>in vitro</em>. Administration of a single 30 mg or multiple 10 mg doses of anastrozole to subjects had no effect on the clearance of antipyrine or urinary recovery of antipyrine metabolites. Based on these <em>in vitro </em>and <em>in vivo </em>results, it is unlikely that the administration of anastrozole 1 mg will result in clinically significant inhibition of cytochrome P450-mediated metabolism of co-administered drugs.</p><p>Antipyrine, cimetidine, tamoxifen and warfarin clinical interaction studies indicate that the coadministration of anastrozole with other drugs is unlikely to result in clinically significant drug interactions mediated by cytochrome P450.</p><p>A review of innovator‟s global clinical trial safety database did not reveal evidence of clinically significant interactions in patients treated with anastrozole who also received other commonly prescribed drugs.</p><p>Estrogen-containing therapies should not be used with anastrozole as they may counteract the goal of achieving estrogen suppression.</p><p>&nbsp;</p><p><strong><u>Drug-Drug Interactions</u></strong></p><p><strong>Warfarin</strong></p><p>The pharmacokinetics and anticoagulant activity of warfarin (25 mg) co-administered with anastrozole (1 mg daily) have been studied in healthy male volunteers. The mean plasma concentrations of anastrozole achieved throughout the warfarin dosing and sampling period were within the range seen in postmenopausal women with advanced breast cancer taking the clinically recommended dose of the drug. Overall, there was no evidence to suggest that anastrozole has any clinically relevant effects on the pharmacokinetics or anti-coagulant activity of warfarin<strong>.</strong></p><p>&nbsp;</p><p><strong>Bisphosphonates</strong></p><p>A review of the innovator‟s global clinical trial safety database showed that there are no clinically significant interactions with bisphosphonates. Results from the SABRE trial demonstrate that anastrozole in combination with the bisphosphonate, risedronate, was well tolerated.</p><p>&nbsp;</p><p><strong>Tamoxifen</strong></p><p>The effect of anastrozole on tamoxifen (20 mg daily) pharmacokinetics has been studied in postmenopausal women with early breast cancer, who were already receiving tamoxifen as adjuvant therapy. There was no evidence of anastrozole having any significant effect on blood levels of tamoxifen compared to placebo (p=0.919).</p><p>Co-administration of anastrozole and tamoxifen did not affect tamoxifen or N-desmethyltamoxifen plasma concentrations, however, anastrozole plasma concentrations were reduced by 27% compared to those achieved with anastrozole alone. Combination treatment of anastrozole with tamoxifen has shown that anastrozole does not have a significant effect on blood levels of tamoxifen; estradiol suppression is consistent with that seen in patients treated with anastrozole alone.</p><p>Results from the ATAC trial (median follow-up of 33 months) suggest that tamoxifen should not be co-administered with anastrozole. The combination did not demonstrate any efficacy or safety benefit when compared to anastrozole or tamoxifen treatment alone, subsequently resulting in the discontinuation of the combination arm from the ATAC trial.</p><p>&nbsp;</p><p><strong>Table 8 Established or potential drug-drug interactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Anastrozole</strong></p></td><td style="vertical-align:top"><p><strong>Ref</strong></p></td><td style="vertical-align:top"><p><strong>Effect</strong></p></td><td style="vertical-align:top"><p><strong>Clinical comment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Tamoxifen</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong>CT</p></td><td style="vertical-align:top"><p>Tamoxifen and metabolite N- desmethyltamoxifen concentrations not affected. Anastrozole concentrations are decreased.</p></td><td style="vertical-align:top"><p>ATAC results indicate that the anastrozole-tamoxifen combination does not demonstrate any efficacy or safety benefits compared to tamoxifen monotherapy.</p></td></tr></tbody></table><p>Legend: C = Case Study; CT = Clinical Trial; T = Theoretical</p><p>&nbsp;</p><p><strong><u>Drug-Food Interactions</u></strong></p><p>Interactions with particular foods have not been established.</p><p>&nbsp;</p><p><strong><u>Drug-Herb Interactions</u></strong></p><p>Interactions with herbal products have not been established. Estrogen-containing herb therapies should not be used with anastrozole as they may counteract the goal of achieving estrogen suppression.</p><p>&nbsp;</p><p><strong><u>Drug-Laboratory Interactions</u></strong></p><p>Anastrozole has not been observed to interfere with routine clinical laboratory tests results.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><strong> Category: </strong>D</p><p>See <strong>4.4, Special Populations.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anastrozole is unlikely to impair the ability of patients to drive and operate machinery. However, asthenia and somnolence have been reported with the use of anastrozole and caution should be observed when driving or operating machinery while such symptoms persist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adverse </u></strong><strong><u>Drug Reaction Overview</u></strong></p><p>Anastrozole has generally been well tolerated. Adverse events have usually been mild to moderate with few withdrawals from treatment due to undesirable events.</p><p>The pharmacological action of anastrozole may give rise to certain expected effects. Arthritis/arthralgia, joint pain/stiffness and hot flushes were reported very commonly (&ge;10%).. Common adverse reactions (&ge;1% - 10%) are: asthenia, , bone pain, myalgia, carpal tunnel syndrome, vaginal dryness, hair thinning (alopecia), rash, nausea, diarrhea, headache and increases in alkaline phosphatase, alanine aminotransferase and aspartate aminotransferase.</p><p>Uncommonly reported adverse reactions (&ge;0.1% - 1%) are: vaginal bleeding, trigger finger, anorexia, hypercholesterolaemia, vomiting, and somnolence, hepatitis and increases in gamma- GT and bilirubin. Rare cases (<u>&gt;</u>0.1% - 0.1%) of cutaneous vasculitis have been observed. Very rare cases (&lt;0.01%) of erythema multiforme, Stevens-Johnson syndrome and allergic reactions including angioedema, urticaria and anaphylaxis have also been reported. These reported frequencies are generated from a number of anastrozole studies as well as post-marketing reports.</p><p>In the ATAC trial, ischemic cardiovascular events were reported more frequently in patients treated with anastrozole compared to those treated with tamoxifen, although the difference was not statistically significant. A retrospective evaluation has shown that this numerical difference was associated with a sub-group of patients with pre-existing ischemic heart disease. A statistical analysis could not be performed on this subgroup evaluation. Serious adverse events continued to be collected during the off-treatment follow-up and the incidence of cardiovascular events reported was similar in the anastrozole and tamoxifen arms (3.9% vs. 3.7%, respectively).</p><p>Events of carpal tunnel syndrome have been reported in patients receiving anastrozole treatment in clinical trials in greater numbers than those receiving treatment with tamoxifen.</p><p>The majority of these events occurred in patients with identifiable risk factors for the development of the condition. In the ATAC adjuvant trial, 83 events of carpal tunnel syndrome occurred in 78 patients in the anastrozole monotherapy arm, and 22 events occurred in 22 patients in the tamoxifen arm.</p><p>Vaginal bleeding has been reported infrequently, mainly in patients during the first few weeks after changing from existing hormonal therapy to treatment with anastrozole. If bleeding persists, further evaluation should be considered.</p><p>&nbsp;</p><p><strong><u>Clinical Trial Adverse Drug Reactions</u></strong></p><p><strong>Adjuvant Treatment of Early Breast Cancer in Postmenopausal Women:</strong></p><p>Anastrozole was generally well tolerated in the ATAC trial. At the time of the 5-year treatment completion analysis, the median duration of adjuvant treatment was 59.8 months and 59.6 months for patients receiving anastrozole 1 mg and tamoxifen 20 mg, respectively. The combination of anastrozole and tamoxifen did not demonstrate any safety benefits in comparison to tamoxifen alone after the results from the first analysis (median duration of treatment was approximately 33 months).</p><p>Anastrozole was associated with statistically significant fewer discontinuations from treatment as a result of an adverse event compared to tamoxifen (11.1% vs. 14.3%) and fewer adverse drug reactions leading to discontinuation (6.5% vs. 8.9%). The incidence of on treatment serious adverse events is significantly lower in patients receiving anastrozole 1 mg relative to tamoxifen 20 mg (33.3% versus 36.0%).</p><p>Adverse events occurring with an incidence of at least 5% in either treatment group during treatment or within 14 days of the end of treatment are presented below in Table 1.</p><p>&nbsp;</p><p><strong>Table 1 Adverse events occurring with an incidence of at least 5% in any treatment group during or within 14 days of the end of treatment from the ATAC trial</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body system and adverse event by COSTART-preferred term</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>Number </strong><strong>(%) of patients (</strong><strong>a)</strong></p><p><strong>33-month analysis </strong></p><p><strong>(data cut-off 29 June 2001)</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>5-year treatment</strong><strong> completion analysis </strong></p><p><strong>(data cut-off 31 March 2004)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong></p><p><strong>1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong></p><p><strong>1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body as a whole</strong></p><p>Asthenia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>483 (15.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>466 (15.1)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>575 (18.6)</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>544 (17.6)</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>432 (14.0)</p></td><td style="vertical-align:top"><p>413 (13.3)</p></td><td style="vertical-align:top"><p>533 (17.2)</p></td><td style="vertical-align:top"><p>485 (15.7)</p></td></tr><tr><td style="vertical-align:top"><p>Back Pain</p></td><td style="vertical-align:top"><p>238 (7.7)</p></td><td style="vertical-align:top"><p>234 (7.6)</p></td><td style="vertical-align:top"><p>321 (10.4)</p></td><td style="vertical-align:top"><p>309 (10.0)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>253 (8.2)</p></td><td style="vertical-align:top"><p>197 (6.4)</p></td><td style="vertical-align:top"><p>314 (10.2)</p></td><td style="vertical-align:top"><p>249 (8.0)</p></td></tr><tr><td style="vertical-align:top"><p>Accidental injury</p></td><td style="vertical-align:top"><p>195(6.3)</p></td><td style="vertical-align:top"><p>189(6.1)</p></td><td style="vertical-align:top"><p>311(10.1)</p></td><td style="vertical-align:top"><p>303(9.8)</p></td></tr><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>197(6.4)</p></td><td style="vertical-align:top"><p>205(6.6)</p></td><td style="vertical-align:top"><p>285(9.2)</p></td><td style="vertical-align:top"><p>276(8.9)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>202(6.5)</p></td><td style="vertical-align:top"><p>211(6.8)</p></td><td style="vertical-align:top"><p>271(8.8)</p></td><td style="vertical-align:top"><p>276(8.9)</p></td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>145(4.7)</p></td><td style="vertical-align:top"><p>115(3.7)</p></td><td style="vertical-align:top"><p>200(6.5)</p></td><td style="vertical-align:top"><p>150(4.80</p></td></tr><tr><td style="vertical-align:top"><p>Flu syndrome</p></td><td style="vertical-align:top"><p>146(4.7)</p></td><td style="vertical-align:top"><p>164(5.3)</p></td><td style="vertical-align:top"><p>175(5.7)</p></td><td style="vertical-align:top"><p>195(6.3)</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasm</p></td><td style="vertical-align:top"><p>101(3.3)</p></td><td style="vertical-align:top"><p>99(3.2)</p></td><td style="vertical-align:top"><p>162(5.2)</p></td><td style="vertical-align:top"><p>144(4.7)</p></td></tr><tr><td style="vertical-align:top"><p>Cyst</p></td><td style="vertical-align:top"><p>96(3.1)</p></td><td style="vertical-align:top"><p>110(3.6)</p></td><td style="vertical-align:top"><p>138(4.5)</p></td><td style="vertical-align:top"><p>162(5.2)</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:560px"><tbody><tr><td style="vertical-align:top; width:170px"><p><strong>Body system and adverse event by COSTART-preferred term</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top; width:179px"><p><strong>Number </strong><strong>(%) of patients (</strong><strong>a)</strong></p><p><strong>33-month analysis (data cut-off 29 June 2001)</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top; width:208px"><p><strong>5-year treatment</strong><strong> completion analysis (data cut-off 31 March 2004)</strong></p></td></tr><tr><td style="vertical-align:top; width:170px"><p>&nbsp;</p></td><td style="vertical-align:top; width:78px"><p><strong>Anastrozole</strong></p><p><strong>1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top; width:92px"><p><strong>Tamoxifen</strong></p><p><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td><td style="vertical-align:top; width:99px"><p><strong>Anastrozole</strong></p><p><strong>1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top; width:110px"><p><strong>Tamoxifen</strong></p><p><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Cardiovascular</strong></p><p>Vasodilation</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong></p><p>1060 (34.3)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong></p><p>1229 (39.7)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong></p><p>1104 (35.7)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong></p><p>1264 (40.9)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Hypertension</p></td><td style="vertical-align:top; width:78px"><p>255 (8.2)</p></td><td style="vertical-align:top; width:92px"><p>218 (7.0)</p></td><td style="vertical-align:top; width:99px"><p>402 (13.0)</p></td><td style="vertical-align:top; width:110px"><p>349 (11.3)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Digestive</strong></p><p>Nausea</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong></p><p>287 (9.3)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong></p><p>281 (9.1)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong></p><p>343 (11.1)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong></p><p>335 (10.8)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Diarrhea</p></td><td style="vertical-align:top; width:78px"><p>206 (6.7)</p></td><td style="vertical-align:top; width:92px"><p>168 (5.4)</p></td><td style="vertical-align:top; width:99px"><p>265 (8.6)</p></td><td style="vertical-align:top; width:110px"><p>216 (7.0)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Constipation</p></td><td style="vertical-align:top; width:78px"><p>183 (5.9)</p></td><td style="vertical-align:top; width:92px"><p>203 (6.6)</p></td><td style="vertical-align:top; width:99px"><p>249 (8.1)</p></td><td style="vertical-align:top; width:110px"><p>252 (8.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Gastrointestinal disorder</p></td><td style="vertical-align:top; width:78px"><p>126 (4.1)</p></td><td style="vertical-align:top; width:92px"><p>104 (3.4)</p></td><td style="vertical-align:top; width:99px"><p>210 (6.8)</p></td><td style="vertical-align:top; width:110px"><p>158 (5.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Dyspepsia</p></td><td style="vertical-align:top; width:78px"><p>150 (4.9)</p></td><td style="vertical-align:top; width:92px"><p>124 (4.0)</p></td><td style="vertical-align:top; width:99px"><p>206 (6.7)</p></td><td style="vertical-align:top; width:110px"><p>169 (5.5)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Haemic </strong><strong>and lymphatic</strong></p><p>Lymphoedema</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong></p><p>247 (8.0)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong></p><p>277 (9.0)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong></p><p>304 (9.8)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong></p><p>341 (11.0)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Anemia</p></td><td style="vertical-align:top; width:78px"><p>73 (2.4)</p></td><td style="vertical-align:top; width:92px"><p>102 (3.3)</p></td><td style="vertical-align:top; width:99px"><p>113 (3.7)</p></td><td style="vertical-align:top; width:110px"><p>159 (5.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Metabolic and nutritional</strong></p></td><td style="vertical-align:top; width:78px"><p>&nbsp;</p></td><td style="vertical-align:top; width:92px"><p>&nbsp;</p></td><td style="vertical-align:top; width:99px"><p>&nbsp;</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Peripheral edema</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong>236 (7.6)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong>246 (8.0)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong>311 (10.1)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong>343 (11.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Weight gain</p></td><td style="vertical-align:top; width:78px"><p>234 (7.6)</p></td><td style="vertical-align:top; width:92px"><p>236 (7.6)</p></td><td style="vertical-align:top; width:99px"><p>285 (9.2)</p></td><td style="vertical-align:top; width:110px"><p>274 (8.9)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Hypercholesterolemia</p></td><td style="vertical-align:top; width:78px"><p>186 (6.0)</p></td><td style="vertical-align:top; width:92px"><p>68 (2.2)</p></td><td style="vertical-align:top; width:99px"><p>278 (9.0)</p></td><td style="vertical-align:top; width:110px"><p>108 (3.5)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Musculoskeletal&nbsp;disorders</strong></p></td><td style="vertical-align:top; width:78px"><p>&nbsp;</p></td><td style="vertical-align:top; width:92px"><p>&nbsp;</p></td><td style="vertical-align:top; width:99px"><p>&nbsp;</p></td><td style="vertical-align:top; width:110px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Arthritis</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong>380 (12.3)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong>296 (9.6)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong>512 (16.6)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong>445 (14.4)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Arthralgia</p></td><td style="vertical-align:top; width:78px"><p>386 (12.5)</p></td><td style="vertical-align:top; width:92px"><p>252 (8.1)</p></td><td style="vertical-align:top; width:99px"><p>467 (15.1)</p></td><td style="vertical-align:top; width:110px"><p>344 (11.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Osteoporosis</p></td><td style="vertical-align:top; width:78px"><p>192 (6.2)</p></td><td style="vertical-align:top; width:92px"><p>134 (4.3)</p></td><td style="vertical-align:top; width:99px"><p>325 (10.5)</p></td><td style="vertical-align:top; width:110px"><p>226 (7.3)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Fracture</p></td><td style="vertical-align:top; width:78px"><p>183 (5.9)</p></td><td style="vertical-align:top; width:92px"><p>115 (3.7)</p></td><td style="vertical-align:top; width:99px"><p>315 (10.2)</p></td><td style="vertical-align:top; width:110px"><p>209 (6.8)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Arthrosis</p></td><td style="vertical-align:top; width:78px"><p>161 (5.2)</p></td><td style="vertical-align:top; width:92px"><p>112 (3.6)</p></td><td style="vertical-align:top; width:99px"><p>207 (6.7)</p></td><td style="vertical-align:top; width:110px"><p>156 (5.0)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Bone pain</p></td><td style="vertical-align:top; width:78px"><p>158 (5.1)</p></td><td style="vertical-align:top; width:92px"><p>139 (4.5)</p></td><td style="vertical-align:top; width:99px"><p>201 (6.5)</p></td><td style="vertical-align:top; width:110px"><p>185 (6.0)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Joint disorder</p></td><td style="vertical-align:top; width:78px"><p>102 (3.3)</p></td><td style="vertical-align:top; width:92px"><p>95 (3.1)</p></td><td style="vertical-align:top; width:99px"><p>184 (6.0)</p></td><td style="vertical-align:top; width:110px"><p>160 (5.2)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Myalgia</p></td><td style="vertical-align:top; width:78px"><p>114 (3.7)</p></td><td style="vertical-align:top; width:92px"><p>103 (3.3)</p></td><td style="vertical-align:top; width:99px"><p>179 (5.8)</p></td><td style="vertical-align:top; width:110px"><p>160 (5.2)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Nervous</strong><strong> system</strong></p><p>Depression</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong></p><p>323 (10.4)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong></p><p>315 (10.2)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong></p><p>413 (13.4)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong></p><p>382 (12.3)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Insomnia</p></td><td style="vertical-align:top; width:78px"><p>253 (8.2)</p></td><td style="vertical-align:top; width:92px"><p>226 (7.3)</p></td><td style="vertical-align:top; width:99px"><p>309 (10.0)</p></td><td style="vertical-align:top; width:110px"><p>281 (9.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Dizziness</p></td><td style="vertical-align:top; width:78px"><p>180 (5.8)</p></td><td style="vertical-align:top; width:92px"><p>191 (6.2)</p></td><td style="vertical-align:top; width:99px"><p>236 (7.6)</p></td><td style="vertical-align:top; width:110px"><p>234 (7.6)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Paraesthesia</p></td><td style="vertical-align:top; width:78px"><p>181 (5.9)</p></td><td style="vertical-align:top; width:92px"><p>106 (3.4)</p></td><td style="vertical-align:top; width:99px"><p>215 (7.0)</p></td><td style="vertical-align:top; width:110px"><p>145 (4.7)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Anxiety</p></td><td style="vertical-align:top; width:78px"><p>147 (4.8)</p></td><td style="vertical-align:top; width:92px"><p>147 (4.8)</p></td><td style="vertical-align:top; width:99px"><p>195 (6.3)</p></td><td style="vertical-align:top; width:110px"><p>180 (5.8)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p><strong>Respiratory</strong></p><p>Pharyngitis</p></td><td style="vertical-align:top; width:78px"><p><strong>&nbsp;</strong></p><p>335 (10.8)</p></td><td style="vertical-align:top; width:92px"><p><strong>&nbsp;</strong></p><p>327 (10.6)</p></td><td style="vertical-align:top; width:99px"><p><strong>&nbsp;</strong></p><p>443 (14.3)</p></td><td style="vertical-align:top; width:110px"><p><strong>&nbsp;</strong></p><p>422 (13.6)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Cough increased</p></td><td style="vertical-align:top; width:78px"><p>194 (6.3)</p></td><td style="vertical-align:top; width:92px"><p>216 (7.0)</p></td><td style="vertical-align:top; width:99px"><p>261 (8.4)</p></td><td style="vertical-align:top; width:110px"><p>287 (9.3)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Dyspnea</p></td><td style="vertical-align:top; width:78px"><p>173 (5.6)</p></td><td style="vertical-align:top; width:92px"><p>164 (5.3)</p></td><td style="vertical-align:top; width:99px"><p>234 (7.6)</p></td><td style="vertical-align:top; width:110px"><p>237 (7.7)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Sinusitis</p></td><td style="vertical-align:top; width:78px"><p>137 (4.4)</p></td><td style="vertical-align:top; width:92px"><p>118 (3.8)</p></td><td style="vertical-align:top; width:99px"><p>184 (6.0)</p></td><td style="vertical-align:top; width:110px"><p>159 (5.1)</p></td></tr><tr><td style="vertical-align:top; width:170px"><p>Bronchitis</p></td><td style="vertical-align:top; width:78px"><p>126 (4.1)</p></td><td style="vertical-align:top; width:92px"><p>107 (3.5)</p></td><td style="vertical-align:top; width:99px"><p>167 (5.4)</p></td><td style="vertical-align:top; width:110px"><p>153 (4.9)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body system and adverse event by COSTART-preferred term</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>Number </strong><strong>(%) of patients (</strong><strong>a)</strong></p><p><strong>33-month analysis (data cut-off 29 June 2001)</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>5-year treatment</strong><strong> completion analysis (data cut-off 31 March 2004)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong></p><p><strong>1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong></p><p><strong>1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong></p><p><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and appendages</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>281 (9.1)</p></td><td style="vertical-align:top"><p>314 (10.1)</p></td><td style="vertical-align:top"><p>333 (10.8)</p></td><td style="vertical-align:top"><p>387 (12.5)</p></td></tr><tr><td style="vertical-align:top"><p>Sweating</p></td><td style="vertical-align:top"><p>112 (3.6)</p></td><td style="vertical-align:top"><p>158 (5.1)</p></td><td style="vertical-align:top"><p>145 (4.7)</p></td><td style="vertical-align:top"><p>177 (5.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Special</strong><strong> senses</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cataract specified</p></td><td style="vertical-align:top"><p>107 (3.5)</p></td><td style="vertical-align:top"><p>116 (3.7)</p></td><td style="vertical-align:top"><p>182 (5.9)</p></td><td style="vertical-align:top"><p>213 (6.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Urogenital</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Breast pain</p></td><td style="vertical-align:top"><p>176 (5.7)</p></td><td style="vertical-align:top"><p>121 (3.9)</p></td><td style="vertical-align:top"><p>251 (8.1)</p></td><td style="vertical-align:top"><p>169 (5.5)</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>169 (5.5)</p></td><td style="vertical-align:top"><p>224 (7.2)</p></td><td style="vertical-align:top"><p>244 (7.9)</p></td><td style="vertical-align:top"><p>313 (10.1)</p></td></tr><tr><td style="vertical-align:top"><p>Vulvovaginitis</p></td><td style="vertical-align:top"><p>169 (5.5)</p></td><td style="vertical-align:top"><p>119 (3.8)</p></td><td style="vertical-align:top"><p>194 (6.3)</p></td><td style="vertical-align:top"><p>150 (4.8)</p></td></tr><tr><td style="vertical-align:top"><p>Breast neoplasm</p></td><td style="vertical-align:top"><p>94 (3.0)</p></td><td style="vertical-align:top"><p>89 (2.9)</p></td><td style="vertical-align:top"><p>164 (5.3)</p></td><td style="vertical-align:top"><p>139 (4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginitis</p></td><td style="vertical-align:top"><p>79 (2.6)</p></td><td style="vertical-align:top"><p>122 (3.9)</p></td><td style="vertical-align:top"><p>125 (4.0)</p></td><td style="vertical-align:top"><p>158 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal hemorrhage (b)</p></td><td style="vertical-align:top"><p>100 (3.2)</p></td><td style="vertical-align:top"><p>151 (4.9)</p></td><td style="vertical-align:top"><p>122 (3.9)</p></td><td style="vertical-align:top"><p>180 (5.8)</p></td></tr><tr><td style="vertical-align:top"><p>Leucorrhea</p></td><td style="vertical-align:top"><p>68 (2.2)</p></td><td style="vertical-align:top"><p>264 (8.5)</p></td><td style="vertical-align:top"><p>86 (2.8)</p></td><td style="vertical-align:top"><p>286 (9.2)</p></td></tr></tbody></table><p>(a) Patients with multiple events in the same category are counted only once in that category.</p><p>Patients with events in more than 1 category are counted once in each of those categories.</p><p>(b) Vaginal hemorrhage without further diagnosis.</p><p>COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms.</p><p>N: Number of patients treated.</p><p>&nbsp;</p><p>Certain adverse events (irrespective of drug causality) and combinations of adverse events were prospectively specified for analysis, based on the known pharmacological properties and side effect profiles of anastrozole and tamoxifen. Tamoxifen was statistically superior to anastrozole for the adverse events of joint disorders and fractures (including fractures of spine, hip and wrist) while anastrozole was statistically superior to tamoxifen for the adverse events of hot flushes, vaginal bleeding, vaginal discharge, endometrial cancer, venous thromboembolic events (including deep thromboembolic events) and ischemic cerebrovascular events.</p><p>A fracture rate of 22 per 1000 patient years was observed on anastrozole and 15 per 1000 patient years with the tamoxifen group with a median follow-up of 68 months. The rate of hip fractures was similar for anastrozole and tamoxifen in the ATAC trial. After a median follow-up of 100 months, fractures were reported more frequently in patients treated with anastrozole in comparison to tamoxifen, both during and off-treatment (13.7% vs 10.1%; see Table 2), but the rate of fracture remained stable between the two groups. During the posttreatment follow-up period, the annual fracture rates were similar in the anastrozole and tamoxifen arms and the increased fracture episode rate seen during treatment was not observed following treatment completion as shown in Figure 1.</p><p>&nbsp;</p><p><strong>Table 2:&nbsp;Incidence of fractures (during or off-trial treatment)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Category</strong></p></td><td rowspan="1" colspan="2" style="vertical-align:top"><p><strong>Number (%) of patients (a)</strong></p><p><strong>2007 update analysis </strong></p><p><strong>(data cut-off 31 March 2007)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong><strong> 1 mg </strong></p><p><strong>(N = 3092)</strong></p></td><td style="vertical-align:top"><p><strong>Tamoxifen</strong><strong> 20 mg </strong></p><p><strong>(N = 3094)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-serious</strong><strong> or serious</strong></p><p>All Fractures</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>425 (13.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>313 (10.1)</p></td></tr><tr><td style="vertical-align:top"><p>Wrist/Colles</p></td><td style="vertical-align:top"><p>95 (3.1)</p></td><td style="vertical-align:top"><p>84 (2.7)</p></td></tr><tr><td style="vertical-align:top"><p>Spine</p></td><td style="vertical-align:top"><p>61 (2.0)</p></td><td style="vertical-align:top"><p>38 (1.20)</p></td></tr><tr><td style="vertical-align:top"><p>Hip</p></td><td style="vertical-align:top"><p>49 (1.6)</p></td><td style="vertical-align:top"><p>42 (1.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Serious</strong></p><p>All fractures</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>212 (6.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>170 (5.5)</p></td></tr><tr><td style="vertical-align:top"><p>Wrist/Colles</p></td><td style="vertical-align:top"><p>49 (1.6)</p></td><td style="vertical-align:top"><p>45 (1.5)</p></td></tr><tr><td style="vertical-align:top"><p>Spine</p></td><td style="vertical-align:top"><p>23 (0.7)</p></td><td style="vertical-align:top"><p>18 (0.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hip</p></td><td style="vertical-align:top"><p>46 (1.5)</p></td><td style="vertical-align:top"><p>40 (1.3)</p></td></tr></tbody></table><p>&nbsp;</p><p>(a) Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.</p><p>Note: Off-trial treatment AEs were SAEs and any fracture event reported as being serious or non-serious that occurred more than 14 days after stopping study treatment (but within 10 years of starting study treatment). AEs starting after the patients first recurrence visit were not reported.</p><p>Note: Off-trial treatment AEs included all off-treatment reports regardless of whether a patient had had a similar report on treatment.</p><p>N: Number of patients treated.</p><p>&nbsp;</p><p><strong>Figure 1: Annual first event rates of all fractures on or off study therapy</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="723" height="490" vspace="0" hspace="0" border="0" style="width:723px;height:490px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>In the ATAC trial, ischemic cardiovascular events were reported more frequently in patients treated with anastrozole compared to those treated with tamoxifen, although the difference was not statistically significant (see Table 3). A retrospective evaluation has shown that this numerical difference was associated with a sub-group of patients with pre-existing ischemic</p><p>heart disease. A statistical analysis could not be performed on this subgroup evaluation. From the 33 month analysis to the 68 month analysis, the incidence of cardiovascular events also remains stable over time between the two treatment groups. The incidence of myocardial infarctions increased by 0.1% in the anastrozole treatment group and 0.2% in the tamoxifen</p><p>treatment group; the incidence of cerebrovascular accidents increased by 0.3% in each treatment group. During the off-treatment follow-up, when serious adverse events continued to be collected, the incidence of myocardial infarctions and cerebrovascular accidents was similar in both treatment groups.</p><p>Table 3 provides a summary of the pre-specified adverse events that occurred in either treatment group during treatment and after cessation of trial therapy.</p><p>&nbsp;</p><p><strong>Table 3 Incidence of pre-specified adverse events occurring in either treatment group during treatment and after cessation of trial therapy from the ATAC trial*</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Adverse Event</strong></p></td><td colspan="6" rowspan="1" style="vertical-align:top"><p><strong>Number </strong><strong>(%) of patients (a)</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>5 year treatment completion analysis (data cut-off 31 March 2004)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Anastrozole</strong><strong> 1 mg</strong></p><p><strong>(N = 3092)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Tamoxifen</strong><strong> </strong><strong>20 mg</strong></p><p><strong>(N = 3094)</strong></p></td><td style="vertical-align:top"><p><strong>Odds ratio (</strong><strong>b)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hot flushes</p></td><td style="vertical-align:top"><p>1104</p></td><td style="vertical-align:top"><p>(35.7)</p></td><td style="vertical-align:top"><p>1264</p></td><td style="vertical-align:top"><p>(40.9)</p></td><td style="vertical-align:top"><p>0.80</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Mood disturbances</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>(19.4)</p></td><td style="vertical-align:top"><p>557</p></td><td style="vertical-align:top"><p>(18.0)</p></td><td style="vertical-align:top"><p>1.10</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue/asthenia</p></td><td style="vertical-align:top"><p>577</p></td><td style="vertical-align:top"><p>(18.7)</p></td><td style="vertical-align:top"><p>544</p></td><td style="vertical-align:top"><p>(17.6)</p></td><td style="vertical-align:top"><p>1.08</p></td><td style="vertical-align:top"><p>0.3</p></td></tr><tr><td style="vertical-align:top"><p>Nausea and vomiting</p></td><td style="vertical-align:top"><p>396</p></td><td style="vertical-align:top"><p>(12.8)</p></td><td style="vertical-align:top"><p>385</p></td><td style="vertical-align:top"><p>(12.4)</p></td><td style="vertical-align:top"><p>1.03</p></td><td style="vertical-align:top"><p>0.7</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal discharge</p></td><td style="vertical-align:top"><p>111</p></td><td style="vertical-align:top"><p>(3.6)</p></td><td style="vertical-align:top"><p>407</p></td><td style="vertical-align:top"><p>(13.2)</p></td><td style="vertical-align:top"><p>0.25</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal bleeding</p></td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>(5.5)</p></td><td style="vertical-align:top"><p>323</p></td><td style="vertical-align:top"><p>(10.4)</p></td><td style="vertical-align:top"><p>0.50</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Joint pain/stiffness</p></td><td style="vertical-align:top"><p>1111</p></td><td style="vertical-align:top"><p>(35.9)</p></td><td style="vertical-align:top"><p>922</p></td><td style="vertical-align:top"><p>(29.8)</p></td><td style="vertical-align:top"><p>1.32</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Fractures</p></td><td style="vertical-align:top"><p>340</p></td><td style="vertical-align:top"><p>(11.0)</p></td><td style="vertical-align:top"><p>238</p></td><td style="vertical-align:top"><p>(7.7)</p></td><td style="vertical-align:top"><p>1.48</p></td><td style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Total Fractures of the spine, hip, or&nbsp;wrist/Colles</p></td><td style="vertical-align:top"><p>148</p></td><td style="vertical-align:top"><p>(4.8)</p></td><td style="vertical-align:top"><p>112</p></td><td style="vertical-align:top"><p>(3.6)</p></td><td style="vertical-align:top"><p>1.34</p></td><td style="vertical-align:top"><p>0.02</p></td></tr><tr><td style="vertical-align:top"><p>Fractures of only Hip (c)</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>(1.2)</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>(1.0)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Fractures of only Spine (c)</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>(1.5)</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>(0.9)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Fractures of only Wrist/Colles (c)</p></td><td style="vertical-align:top"><p>72</p></td><td style="vertical-align:top"><p>(2.3)</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>(2.0)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Cataracts</p></td><td style="vertical-align:top"><p>191</p></td><td style="vertical-align:top"><p>(6.2)</p></td><td style="vertical-align:top"><p>219</p></td><td style="vertical-align:top"><p>(7.1)</p></td><td style="vertical-align:top"><p>0.86</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Ischemic cardiovascular disease</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>(4.4)</p></td><td style="vertical-align:top"><p>119</p></td><td style="vertical-align:top"><p>(3.8)</p></td><td style="vertical-align:top"><p>1.16</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Angina Pectoris (c)</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>(2.4)</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>(1.8)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial infarct (c)</p></td><td style="vertical-align:top"><p>42</p></td><td style="vertical-align:top"><p>(1.4)</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>(1.3)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Coronary artery disorder (c)</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>(0.7)</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>(0.9)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Myocardial ischemia (c)</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>(0.8)</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>(0.5)</p></td><td style="vertical-align:top"><p>NC</p></td><td style="vertical-align:top"><p>NC</p></td></tr><tr><td style="vertical-align:top"><p>Venous thromboembolic events</p></td><td style="vertical-align:top"><p>95</p></td><td style="vertical-align:top"><p>(3.1)</p></td><td style="vertical-align:top"><p>151</p></td><td style="vertical-align:top"><p>(4.9)</p></td><td style="vertical-align:top"><p>0.62</p></td><td style="vertical-align:top"><p>0.0003</p></td></tr><tr><td style="vertical-align:top"><p>Deep venous thromboembolic events</p></td><td style="vertical-align:top"><p>57</p></td><td style="vertical-align:top"><p>(1.8)</p></td><td style="vertical-align:top"><p>83</p></td><td style="vertical-align:top"><p>(2.7)</p></td><td style="vertical-align:top"><p>0.68</p></td><td style="vertical-align:top"><p>0.03</p></td></tr><tr><td style="vertical-align:top"><p>Ischemic cerebrovascular events</p></td><td style="vertical-align:top"><p>67</p></td><td style="vertical-align:top"><p>(2.2)</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>(3.0)</p></td><td style="vertical-align:top"><p>0.71</p></td><td style="vertical-align:top"><p>0.03</p></td></tr><tr><td style="vertical-align:top"><p>Endometrial cancer (d)</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>(0.2)</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>(0.8)</p></td><td style="vertical-align:top"><p>0.29</p></td><td style="vertical-align:top"><p>0.02</p></td></tr></tbody></table><p>* All adverse events occurring during treatment or within 14 days of the end of treatment; all serious adverse events and all non-serious fractures occurring after 14 days from the end of treatment and prior to the confirmation of recurrence of breast cancer.</p><p>(a)&nbsp;Patients with multiple events in the same category are counted only once in that category. Patients with events in more than 1 category are counted once in each of those categories.</p><p>(b) Odds ratios of &lt;1.00 indicate that treatment with anastrozole 1 mg is associated with a lower incidence of a specific event than tamoxifen 20 mg.</p><p>(c) Individual COSTART&ndash;preferred terms for a particular category of event &ndash; the broader category was the &bdquo;pre-specified adverse event‟.</p><p>(d) Percentages calculated based upon the numbers of patients with an intact uterus at baseline (N=2229 for anastrozole and N=2236 for tamoxifen).</p><p>N: Number of patients treated.</p><p>NC: Not calculated.</p><p>&nbsp;</p><p><strong>Patients with Advanced Breast Cancer:</strong></p><p>Two controlled clinical trials involving postmenopausal women with advanced breast cancer, compared treatment with tamoxifen (20 mg daily) versus treatment with anastrozole (1 mg daily). Table 4 presents adverse events reported in these trials with an incidence of greater than 5% in either treatment group, regardless of causality.</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:66.6pt;margin-top:14.2pt;width:478.9pt;
 height:.1pt;z-index:1216;mso-position-horizontal-relative:page' coordorigin="1332,284"
 coordsize="9578,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1332;top:284;width:9578;
  height:2' coordorigin="1332,284" coordsize="9578,0" path="m1332,284r9578,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><strong><img width="640" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Table 4 Number (%) of patients with adverse events from Trials 0027 and 0030*</strong><!--[if gte vml 1]><v:group id="_x0000_s1029"
 style='position:absolute;left:0;text-align:left;margin-left:66.6pt;
 margin-top:28.45pt;width:478.9pt;height:.1pt;z-index:1240;
 mso-position-horizontal-relative:page' coordorigin="1332,569" coordsize="9578,2">
 <v:shape id="_x0000_s1030" style='position:absolute;left:1332;top:569;width:9578;
  height:2' coordorigin="1332,569" coordsize="9578,0" path="m1332,569r9578,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="640" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><table border="1" cellspacing="1" cellpadding="1" style="width:527px"><tbody><tr><td><p><strong>Adverse Event</strong><strong> by Body System</strong></p></td><td style="width:167px"><p><strong>Anastrozole</strong><strong> 1 mg</strong></p><p><strong>(n = 506)</strong></p></td><td style="width:126px"><p><strong>Tamoxifen</strong><strong> 20 mg</strong></p><p><strong>(n = 511)</strong></p></td></tr><tr><td><p><strong>Body a Whole</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Asthenia</p></td><td style="width:167px"><p>83 (16.4)</p></td><td style="width:126px"><p>81 (15.9)</p></td></tr><tr><td><p>Pain</p></td><td style="width:167px"><p>70 (13.8)</p></td><td style="width:126px"><p>73 (14.3)</p></td></tr><tr><td><p>Back Pain</p></td><td style="width:167px"><p>60 (11.9)</p></td><td style="width:126px"><p>68 (13.3)</p></td></tr><tr><td><p>Headache</p></td><td style="width:167px"><p>47 (9.3)</p></td><td style="width:126px"><p>40 (7.8)</p></td></tr><tr><td><p>Chest Pain</p></td><td style="width:167px"><p>37 (7.3)</p></td><td style="width:126px"><p>37 (7.2)</p></td></tr><tr><td><p>Flu Syndrome</p></td><td style="width:167px"><p>35 (6.9)</p></td><td style="width:126px"><p>30 (5.9)</p></td></tr><tr><td><p>Pelvic Pain</p></td><td style="width:167px"><p>23 (4.5)</p></td><td style="width:126px"><p>30 (5.9)</p></td></tr><tr><td><p><strong>Cardiovascular</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Vasodilation</p></td><td style="width:167px"><p>128 (25.3)</p></td><td style="width:126px"><p>106 (20.7)</p></td></tr><tr><td><p>Hypertension</p></td><td style="width:167px"><p>25 (4.9)</p></td><td style="width:126px"><p>36 (7.0)</p></td></tr><tr><td><p><strong>Digestive</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Nausea</p></td><td style="width:167px"><p>94 (18.6)</p></td><td style="width:126px"><p>106 (20.7)</p></td></tr><tr><td><p>Constipation</p></td><td style="width:167px"><p>47 (9.3)</p></td><td style="width:126px"><p>66 (12.9)</p></td></tr><tr><td><p>Abdominal Pain</p></td><td style="width:167px"><p>40 (7.9)</p></td><td style="width:126px"><p>38 (7.4)</p></td></tr><tr><td><p>Diarrhea</p></td><td style="width:167px"><p>40 (7.9)</p></td><td style="width:126px"><p>33 (6.5)</p></td></tr><tr><td><p>Vomiting</p></td><td style="width:167px"><p>38 (7.5)</p></td><td style="width:126px"><p>36 (7.0)</p></td></tr><tr><td><p>Anorexia</p></td><td style="width:167px"><p>26 (5.1)</p></td><td style="width:126px"><p>46 (9.0)</p></td></tr><tr><td><p><strong>Metabolic and Nutritional</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Peripheral Edema</p></td><td style="width:167px"><p>51 (10.1)</p></td><td style="width:126px"><p>41 (8.0)</p></td></tr><tr><td><p><strong>Musculoskeletal Disorders</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Bone Pain</p></td><td style="width:167px"><p>54 (10.7)</p></td><td style="width:126px"><p>52 (10.2)</p></td></tr><tr><td><p><strong>Nervous System</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Insomnia</p></td><td style="width:167px"><p>30 (5.9)</p></td><td style="width:126px"><p>28 (5.5)</p></td></tr><tr><td><p>Dizziness</p></td><td style="width:167px"><p>30 (5.9)</p></td><td style="width:126px"><p>22 (4.3)</p></td></tr><tr><td><p>Depression</p></td><td style="width:167px"><p>23 (4.5)</p></td><td style="width:126px"><p>32 (6.3)</p></td></tr><tr><td><p>Hypertonia</p></td><td style="width:167px"><p>16 (3.2)</p></td><td style="width:126px"><p>26 (5.1)</p></td></tr><tr><td><p><strong>Respiratory</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Cough Increased</p></td><td style="width:167px"><p>55 (10.9)</p></td><td style="width:126px"><p>52 (10.2)</p></td></tr><tr><td><p>Dyspnea</p></td><td style="width:167px"><p>51 (10.1)</p></td><td style="width:126px"><p>47 (9.2)</p></td></tr><tr><td><p>Pharyngitis</p></td><td style="width:167px"><p>49 (9.7)</p></td><td style="width:126px"><p>68 (13.3)</p></td></tr><tr><td><p><strong>Skin and Appendages</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Rash</p></td><td style="width:167px"><p>38 (7.5)</p></td><td style="width:126px"><p>34 (6.7)</p></td></tr><tr><td><p><strong>Urogenital</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Leucorrhea</p></td><td style="width:167px"><p>9 (1.8)</p></td><td style="width:126px"><p>31 (6.1)</p></td></tr></tbody></table><p>* A patient may have more than one adverse event.</p><p>Based on results from the established safety profiles of anastrozole and tamoxifen, the incidences of nine pre-specified adverse event categories, potentially causally related to one or both therapies because of their pharmacology, were statistically analyzed. No statistically significant differences were seen between treatment groups. The results are shown in Table 5.</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:66.6pt;margin-top:14.2pt;width:478.9pt;
 height:.1pt;z-index:1312;mso-position-horizontal-relative:page' coordorigin="1332,284"
 coordsize="9578,2">
 <v:shape id="_x0000_s1027" style='position:absolute;left:1332;top:284;width:9578;
  height:2' coordorigin="1332,284" coordsize="9578,0" path="m1332,284r9578,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><strong><img width="640" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Table 5 Number (%) of patients from Trials 0027 and 0030*</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:527px"><tbody><tr><td><p><strong>Adverse Event</strong><strong> by Body System</strong></p></td><td style="width:167px"><p><strong>Anastrozole</strong><strong> 1 mg</strong></p><p><strong>(n = 506)</strong></p></td><td style="width:126px"><p><strong>Tamoxifen</strong><strong> 20 mg</strong></p><p><strong>(n = 511)</strong></p></td></tr><tr><td><p><strong>Body a Whole</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Tumor Flare</p></td><td style="width:167px"><p>15 (3.0)</p></td><td style="width:126px"><p>18 (3.5)</p></td></tr><tr><td><p><strong>Cardiovascular</strong></p></td><td style="width:167px"><p>&nbsp;</p></td><td style="width:126px"><p>&nbsp;</p></td></tr><tr><td><p>Hot Flushes</p></td><td style="width:167px"><p>134 (26.5)</p></td><td style="width:126px"><p>118 (23.1)</p></td></tr><tr><td><p>Thromboembolic Diseases</p></td><td style="width:167px"><p>23 (4.5)</p></td><td style="width:126px"><p>39 (7.6)</p></td></tr><tr><td><p><strong>Digestive</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Gastrointestinal Disturbances</p></td><td style="width:167px"><p>170 (33.6)</p></td><td style="width:126px"><p>196 (38.4)</p></td></tr><tr><td><p><strong>Metabolic and Nutritional</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Weight Gain</p></td><td style="width:167px"><p>11 (2.2)</p></td><td style="width:126px"><p>8 (1.6)</p></td></tr><tr><td><p><strong>Nervous System</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Depression</p></td><td style="width:167px"><p>23 (4.5)</p></td><td style="width:126px"><p>32 (6.3)</p></td></tr><tr><td><p>Lethargy</p></td><td style="width:167px"><p>6 (1.2)</p></td><td style="width:126px"><p>15 (2.9)</p></td></tr><tr><td><p><strong>Urogenital</strong></p></td><td style="width:167px">&nbsp;</td><td style="width:126px">&nbsp;</td></tr><tr><td><p>Vaginal Dryness</p></td><td style="width:167px"><p>15 (3.0)</p></td><td style="width:126px"><p>13 (2.5)</p></td></tr><tr><td><p>Vaginal Bleeding</p></td><td style="width:167px"><p>5 (1.0)</p></td><td style="width:126px"><p>11 (2.2)</p></td></tr></tbody></table><p>* Patients may appear in more than one row.</p><p>The low incidence of vaginal bleeding and vaginal discharge was consistent with the known pharmacology of anastrozole, which would be predicted to have no estrogenic effect, and no effect on the endometrium. Despite the lack of estrogenic activity, there was no increase in myocardial infarction or pathological fracture when compared with tamoxifen. There was a low incidence of thromboembolic disease.</p><p>&nbsp;</p><p><strong>Patients with Advanced Breast Cancer Who had Disease Progression Following Tamoxifen Therapy</strong></p><p>For two controlled clinical trials comparing anastrozole (1 mg and 10 mg) versus megestrol acetate (160 mg), adverse events reported in greater than 5% of the patients in any of the treatment groups, regardless of causality, are presented in Table 6.<!--[if gte vml 1]><v:group id="_x0000_s1029"
 style='position:absolute;left:0;text-align:left;margin-left:66.6pt;
 margin-top:28pt;width:461.5pt;height:.1pt;z-index:1360;
 mso-position-horizontal-relative:page' coordorigin="1332,560" coordsize="9230,2">
 <v:shape id="_x0000_s1030" style='position:absolute;left:1332;top:560;width:9230;
  height:2' coordorigin="1332,560" coordsize="9230,0" path="m1332,560r9230,e"
  filled="f" strokeweight=".58pt">
  <v:path arrowok="t"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><strong><img width="617" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Table 6 Number (n) and percentage of patients with adverse events from Trials 0004 and 0005*</strong><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026" style='width:462.8pt;
 height:.6pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9256,12">
 <o:lock v:ext="edit" rotation="t" position="t"/>
 <v:group id="_x0000_s1027" style='position:absolute;left:6;top:6;width:9245;
  height:2' coordorigin="6,6" coordsize="9245,2">
  <v:shape id="_x0000_s1028" style='position:absolute;left:6;top:6;width:9245;
   height:2' coordorigin="6,6" coordsize="9245,0" path="m6,6r9244,e" filled="f"
   strokeweight=".58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="618" height="2" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman"'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:462.8pt;
 height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
 <o:lock v:ext="edit" rotation="t" position="t"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Event</strong><strong> by Body System</strong></p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong><strong> 1 mg</strong></p><p><strong>(n = 262) n (%)</strong></p></td><td style="vertical-align:top; width:115px"><p><strong>Anastrozole</strong><strong> 10 mg</strong></p><p><strong>(n = 246) n (%)</strong></p></td><td style="vertical-align:top; width:161px"><p><strong>Megestrol</strong><strong> Acetate (160 mg)</strong></p><p><strong>n = 253</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Body as a Whole</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:115px">&nbsp;</td><td style="vertical-align:top; width:161px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>42 (16.0)</p></td><td style="vertical-align:top; width:115px"><p>33 (13.4)</p></td><td style="vertical-align:top; width:161px"><p>47 (18.6)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>34 (13.0)&nbsp;&nbsp;</p></td><td style="vertical-align:top; width:115px"><p>44 (17.9)</p></td><td style="vertical-align:top; width:161px"><p>24 (9.5)</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>28 (10.7)</p></td><td style="vertical-align:top; width:115px"><p>38 (15.4)</p></td><td style="vertical-align:top; width:161px"><p>29 (11.5)</p></td></tr><tr><td style="vertical-align:top"><p>Back Pain</p></td><td style="vertical-align:top"><p>28 (10.7)</p></td><td style="vertical-align:top; width:115px"><p>26 (10.6)</p></td><td style="vertical-align:top; width:161px"><p>19 (7.5)</p></td></tr><tr><td style="vertical-align:top"><p>Pelvic Pain</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top; width:115px"><p>17 (6.9)</p></td><td style="vertical-align:top; width:161px"><p>13 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p>Chest Pain</p></td><td style="vertical-align:top"><p>13 (5.0)</p></td><td style="vertical-align:top; width:115px"><p>18 (7.3)</p></td><td style="vertical-align:top; width:161px"><p>13 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiovascular</strong></p><p>Hot Flushes</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>32 (12.2)</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p><p>29 (10.6)</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p><p>21 (8.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Digestive</strong></p><p>Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>41 (15.6)</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p><p>48 (19.5)</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p><p>28 (11.1)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>24 (9.2)</p></td><td style="vertical-align:top; width:115px"><p>26 (10.6)</p></td><td style="vertical-align:top; width:161px"><p>16 (6.3)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>22 (8.4)</p></td><td style="vertical-align:top; width:115px"><p>18 (7.3)</p></td><td style="vertical-align:top; width:161px"><p>7 (2.8)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>18 (6.9)</p></td><td style="vertical-align:top; width:115px"><p>18 (7.3)</p></td><td style="vertical-align:top; width:161px"><p>21 (8.3)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain</p></td><td style="vertical-align:top"><p>18 (6.9)</p></td><td style="vertical-align:top; width:115px"><p>14 (5.7)</p></td><td style="vertical-align:top; width:161px"><p>18 (7.1)</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>18 (6.9)</p></td><td style="vertical-align:top; width:115px"><p>19 (7.7)</p></td><td style="vertical-align:top; width:161px"><p>11 (4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Dry Mouth</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top; width:115px"><p>11 (4.5)</p></td><td style="vertical-align:top; width:161px"><p>13 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolic and&nbsp;Nutritional</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Peripheral Edema</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top; width:115px"><p>21 (8.5)</p></td><td style="vertical-align:top; width:161px"><p>28 (11.1)</p></td></tr><tr><td style="vertical-align:top"><p>Weight Gain</p></td><td style="vertical-align:top"><p>4 (1.5)</p></td><td style="vertical-align:top; width:115px"><p>9 (3.7)</p></td><td style="vertical-align:top; width:161px"><p>30 (11.9)</p></td></tr><tr><td style="vertical-align:top"><p>Increased Appetite</p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top; width:115px"><p>1 (0.4)</p></td><td style="vertical-align:top; width:161px"><p>13 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal Disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bone Pain</p></td><td style="vertical-align:top"><p>17 (6.5)</p></td><td style="vertical-align:top; width:115px"><p>26 (11.8)</p></td><td style="vertical-align:top; width:161px"><p>19 (7.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous</strong><strong> System</strong></p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16 (6.1)</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p><p>12 (4.9)</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p><p>15 (5.9)</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top; width:115px"><p>6 (2.4)</p></td><td style="vertical-align:top; width:161px"><p>5 (2.0)</p></td></tr><tr><td style="vertical-align:top"><p>Paresthesia</p></td><td style="vertical-align:top"><p>12 (4.6)</p></td><td style="vertical-align:top; width:115px"><p>15 (6.1)</p></td><td style="vertical-align:top; width:161px"><p>9 (3.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory</strong></p><p>Dyspnea</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>24 (9.2)</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p><p>27 (11.0)</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p><p>53 (20.9)</p></td></tr><tr><td style="vertical-align:top"><p>Cough Increased</p></td><td style="vertical-align:top"><p>22 (8.4)</p></td><td style="vertical-align:top; width:115px"><p>18 (7.3)</p></td><td style="vertical-align:top; width:161px"><p>19 (7.5)</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top"><p>16 (6.1)</p></td><td style="vertical-align:top; width:115px"><p>23 (9.3)</p></td><td style="vertical-align:top; width:161px"><p>15 (5.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Appendages</strong></p><p>Rash</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15 (5.7)</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p><p>15 (6.1)</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p><p>19 (7.5)</p></td></tr><tr><td style="vertical-align:top"><p>Sweating</p></td><td style="vertical-align:top"><p>4 (1.5)</p></td><td style="vertical-align:top; width:115px"><p>3 (1.2)</p></td><td style="vertical-align:top; width:161px"><p>16 (6.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Urogenital</strong></p><p>Vaginal Hemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>6 (2.3)</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p><p>4 (1.6)</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p><p>13 (5.1)</p></td></tr></tbody></table><p>* A patient may have more than one adverse event.</p><p>Other less frequent (2% to 5%) adverse experiences reported in patients receiving anastrozole 1 mg in the two pivotal clinical trials are listed below. These adverse experiences are listed by body system and are in order of decreasing frequency within each body system regardless of assessed causality.</p><p><strong>Body as a Whole</strong>: Flu syndrome; fever; neck pain; malaise; accidental injury; infection</p><p><strong>Cardiovascular: </strong>Hypertension; thrombophlebitis</p><p><strong>Hepatic</strong>: Gamma GT increased; SGOT increased; SGPT increased</p><p><strong>Hematologic</strong>: Anemia; leucopenia</p><p><strong>Metabolic</strong><strong> and Nutritional</strong>: Alkaline phosphatase increased; weight loss</p><p>Mean serum total cholesterol levels increased by 0.5 mmol/L among patients receiving anastrozole. Increases in LDL cholesterol have been shown to contribute to these changes.</p><p><strong>Musculoskeletal</strong>: Myalgia; arthralgia; pathological fracture</p><p><strong>Nervous: </strong>Somnolence; confusion; insomnia; anxiety; nervousness</p><p><strong>Respiratory</strong>: Sinusitis; bronchitis; rhinitis</p><p><strong>Skin and Appendages</strong>: Hair thinning; pruritus</p><p><strong>Urogenital</strong>: Urinary tract infection; breast pain</p><p>The incidence of the following adverse event groups, potentially causally related to one or both of the therapies because of their pharmacology, were statistically analyzed: weight gain, edema, thromboembolic disease, gastrointestinal disturbance, hot flushes, and vaginal dryness. These six groups, and the adverse events captured in the groups, were prospectively defined. The results are shown in Table 7.</p><p><strong>Table 7 Number (n) and percentage of patients from Trials 0004 and 0005</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Event</strong><strong> by Body System</strong></p></td><td style="vertical-align:top"><p><strong>Anastrozole</strong><strong> 1 mg</strong></p><p><strong>(n = 262) n (%)</strong></p></td><td style="vertical-align:top; width:115px"><p><strong>Anastrozole</strong><strong> 10 mg</strong></p><p><strong>(n = 246) n (%)</strong></p></td><td style="vertical-align:top; width:161px"><p><strong>Megestrol</strong><strong> Acetate (160 mg)</strong></p><p><strong>n = 253</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiovascular</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:115px">&nbsp;</td><td style="vertical-align:top; width:161px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hot Flushes</p></td><td style="vertical-align:top"><p>42 (16.0)</p></td><td style="vertical-align:top; width:115px"><p>33 (13.4)</p></td><td style="vertical-align:top; width:161px"><p>47 (18.6)</p></td></tr><tr><td style="vertical-align:top"><p>Thromboembolic</p></td><td style="vertical-align:top"><p>34 (13.0)&nbsp;&nbsp;</p></td><td style="vertical-align:top; width:115px"><p>44 (17.9)</p></td><td style="vertical-align:top; width:161px"><p>24 (9.5)</p></td></tr><tr><td style="vertical-align:top"><p>Disease</p></td><td style="vertical-align:top"><p>28 (10.7)</p></td><td style="vertical-align:top; width:115px"><p>38 (15.4)</p></td><td style="vertical-align:top; width:161px"><p>29 (11.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Digestive </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:115px"><p>&nbsp;</p></td><td style="vertical-align:top; width:161px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disturbance</p></td><td style="vertical-align:top"><p>77 (29.4)</p></td><td style="vertical-align:top; width:115px"><p>81 (32.9)</p></td><td style="vertical-align:top; width:161px"><p>54 (21.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolic and Nutritiona</strong>l</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:115px">&nbsp;</td><td style="vertical-align:top; width:161px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Edema</p></td><td style="vertical-align:top"><p>19 (7.3)</p></td><td style="vertical-align:top; width:115px"><p>28 (11.4)</p></td><td style="vertical-align:top; width:161px"><p>35 (13.8)</p></td></tr><tr><td style="vertical-align:top"><p>Weight Gain</p></td><td style="vertical-align:top"><p>4 (1.5)</p></td><td style="vertical-align:top; width:115px"><p>10 (4.1)</p></td><td style="vertical-align:top; width:161px"><p>30 (11.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Urogenital</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top; width:115px">&nbsp;</td><td style="vertical-align:top; width:161px">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vaginal Dryness</p></td><td style="vertical-align:top"><p>5 (1.9)</p></td><td style="vertical-align:top; width:115px"><p>3 (1.2)</p></td><td style="vertical-align:top; width:161px"><p>2 (0.8)</p></td></tr></tbody></table><p>More patients treated with megestrol acetate reported weight gain as an adverse event compared to patients treated with anastrozole 1 mg (p&lt;0.0001). Other differences were not statistically significant.</p><p>An examination of the magnitude of change in weight in all patients was also conducted. Thirty- four percent (87/253) of the patients treated with megestrol acetate experienced weight gain of 5% or more and 11% (27/253) of the patients treated with megestrol acetate experienced weight gain of 10% or more. Among patients treated with anastrozole 1 mg, 13% (33/262) experienced weight gain of 5% or more and 3% (6/262) experienced weight gain of 10% or more. On average, this 5 to 10% weight gain represented between 6 and 12 pounds.</p><p>No patients receiving anastrozole or megestrol acetate discontinued treatment due to drug related weight gain.</p><p>&nbsp;</p><p><strong><u>Abnormal Hematologic and Clinical Chemistry Findings</u></strong></p><p>Systematic collection of laboratory results (including total cholesterol) was not performed as specific endpoints in the ATAC trial. Abnormal laboratory results in ATAC are reported as an adverse event. During the ATAC trial, more patients receiving anastrozole were reported to have elevated serum cholesterol levels compared to patients receiving tamoxifen (9% versus 3.5%, respectively). In the SABRE trial, which was designed to specifically evaluate lipid levels in patients on anastrozole, no difference was observed in levels of low density lipoprotein- cholesterol (LDL-C), total cholesterol or triglycerides in patients taking anastrozole for 12 months compared to levels prior to commencing anastrozole treatment.</p><p>There was a statistically significant increase in high density lipoprotein-cholesterol (HDL-C)</p><p>in patients taking anastrozole for 12 months compared to levels prior to commencing anastrozole treatment (see Clinical Trials, Adjuvant treatment of breast cancer in postmenopausal women &ndash; assessment of lipids). On the basis of the SABRE data, no specific requirements for lipid monitoring due to anastrozole therapy are recommended.</p><p>&nbsp;</p><p><strong><u>Post-Market Adverse Drug Reactions</u></strong></p><p>A case of severe acute hepatitis has been reported. Although late onset hepatotoxicity due to previous chemotherapy could not be ruled out, the temporal evidence suggested anastrozole &nbsp;as a possible cause. Cases of toxic hepatitis have been reported in association with anastrozole administration.</p><p>Cases of cutaneous vasculitis (including some reports of Henoch-Sch&ouml;nlein purpura) have been associated with anastrozole administration and symptoms have been reported to resolve within 10-30 days of discontinuing the drug, either spontaneously or with additional treatments.</p><p>Severe hypercalcaemia with high serum parathyroid hormone (PTH) levels was reported in a 65-year old woman on anastrozole. All parathyroid glands were considered normal and the hypercalcaemia and high PTH levels resolved within one month of anastrozole withdrawal. Calcium and PTH values increased to high levels again within 6 weeks of resumption of anastrozole.</p><p>Cases of paraesthesia (pain, numbness, and tingling of skin) and dysgeusia (taste loss and perversion) have been associated with anastrozole administration.</p><p>&nbsp;</p><p>- To report any side effects:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p><strong>The</strong><strong> </strong><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Drug Safety Centre (NPC)</strong></p><p>Fax: +966‐11‐205‐7662</p><p>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</p><p>Toll free phone: 8002490000</p><p>E‐mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.</p></td></tr></tbody></table><p>&nbsp;</p><p>There is limited clinical experience of accidental overdosage. Acute toxicity was seen in animals at a dose greater than 45 mg/kg (equivalent to 2.7 g). Clinical trials have been conducted with various dosages of anastrozole, up to 60 mg in a single dose given to healthy male volunteers and up to 10 mg daily given to postmenopausal women with advanced breast cancer; these dosages were well tolerated. A single dose of anastrozole that results in life-threatening symptoms has not been established.</p><p>There is no specific antidote to overdosage and treatment must be symptomatic. In the management of an overdose, consideration should be given to the possibility that multiple agents may have been taken. Vomiting may be induced if the patient is alert. Dialysis may be helpful because anastrozole is not highly protein bound. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated. For management of suspected drug overdose, contact your regional Poison Control Centre.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC Code: &nbsp;</strong>L02BG03</p><p><strong><u>Mechanism of Action</u></strong></p><p>Many breast cancers have estrogen receptors and growth of these tumours can be stimulated by estrogens. In postmenopausal women, the principal source of circulating estrogen (primarily estrone) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, such as adipose tissue, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumour-generated estrogens is uncertain.</p><p>Treatment of breast cancer has included efforts to decrease estrogen levels by ovariectomy pre- menopausally and by use of anti-estrogens and progestational agents both pre- and postmenopausally, and these interventions lead to decreased tumour mass or delayed progression of tumour growth in some women.</p><p>Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.</p><p>&nbsp;</p><p><strong><u>Pharmacodynamics</u></strong></p><p>Inhibition of aromatase activity is primarily due to anastrozole, the parent drug.</p><p>The relationship between dose and response, measured as suppression of serum estradiol, was studied in postmenopausal women. Daily doses of anastrozole at 1 mg for 14 days produced estradiol suppression of greater than 80%. Suppression of serum estradiol was maintained for up to 6 days after cessation of daily dosing with 1 mg anastrozole.</p><p>In a study of 14 postmenopausal women diagnosed with locally advanced (Stage T3-T4) breast cancer with non-inflammatory, estrogen-receptor positive tumours, anastrozole was shown to be a potent suppressor of intra-tumoural estrogen levels. Following use as a 15- week primary systemic treatment (prior to any local surgery and/or radiotherapy), anastrozole suppressed intra- tumoural concentrations of estradiol (E2), estrone (E1) and estrone sulfate (E1S) to mean values of 11.1%, 16.7% and 26.6%, respectively, of baseline levels. Three patients had intra-tumoural levels of E2, E1&nbsp;and E1S suppressed below assay detection limits.</p><p>The selectivity of anastrozole to the aromatase enzyme, rather than other cytochrome P450 enzymes controlling glucocorticoid and mineralocorticoid synthesis in the adrenal gland, has been established. Furthermore, provocative stimulation of the adrenal glands by ACTH in subjects under treatment with anastrozole up to 10 mg, produced a normal response in terms of cortisol and aldosterone secretion. Therefore, patients treated with anastrozole do not require glucocorticoid or mineralocorticoid replacement therapy.</p><p>Anastrozole does not possess direct progestogenic, androgenic or estrogenic activity and does not interfere with secretion of thyroid stimulating hormone (TSH).</p><p>Because of its pharmacological action, patients with estrogen and/or progesterone receptorpositive disease are the most appropriate population for anastrozole therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacokinetics</u></strong></p><p><strong>Absorption: </strong>Absorption of anastrozole is rapid and maximum plasma concentrations typically occur within 2 hours of dosing under fasted conditions. Studies with radiolabeled drug have demonstrated that orally administered anastrozole is well absorbed into the systemic circulation. Food reduces the rate, but not the overall extent of anastrozole absorption.</p><p><strong>Distribution: </strong>The pharmacokinetics of anastrozole are linear over the dose range of 1 to 20 mg and do not change with repeated dosing. Consistent with the 50-hour plasma elimination half- life, plasma concentrations of anastrozole approach steady-state concentrations after 7 days of once daily dosing and are approximately three- to four-fold higher than the concentrations observed after a single dose of anastrozole. The protein binding of anastrozole to plasma proteins is about 40% and independent of concentration over a range, which includes therapeutic concentrations.</p><p><strong>Metabolism: </strong>Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. Three metabolites of anastrozole (triazole, a glucuronide conjugate of hydroxy- anastrozole, and a glucuronide conjugate of anastrozole itself) have been identified in human plasma or urine. Several minor (less than 5% of the radioactive dose) metabolites excreted in the urine have not been identified. The major metabolite of anastrozole in the circulation, triazole, lacks pharmacologic activity.</p><p><strong>Excretion: </strong>Studies in postmenopausal women with radiolabeled anastrozole demonstrated that elimination occurs primarily via metabolism (approximately 85%) and to a lesser extent renal excretion of unchanged anastrozole (approximately 11%). Anastrozole is eliminated slowly with a plasma elimination half-life of approximately 50 hours in postmenopausal women.</p><p>&nbsp;</p><p><strong><u>Special Populations and Conditions</u></strong></p><p><strong>Geriatrics: </strong>Anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer. The pharmacokinetics were similar in volunteers and in patients and no age related effects were seen.</p><p><strong>Race: </strong>Anastrozole pharmacodynamics and pharmacokinetics have been studied in healthy, postmenopausal women in Japan, dosed for 16 days. The pharmacodynamic effect and pharmacokinetics of anastrozole 1 mg daily were similar in Japanese and Caucasian volunteers, and there was no indication that there would be any clinically significant differences in therapeutic responses to anastrozole between Japanese and Caucasian patients with breast cancer.</p><p><strong>Hepatic Insufficiency: </strong>Anastrozole pharmacokinetics have been investigated in subjects with stable hepatic cirrhosis related to alcohol abuse. The apparent oral clearance of anastrozole was approximately 30% lower in subjects with hepatic cirrhosis than in control subjects with normal liver function. However, plasma anastrozole concentrations in the subjects with hepatic cirrhosis are within the range of concentrations seen in normal subjects across all clinical trials. Dosage adjustment in patients with mild to moderate hepatic impairment is not necessary. Anastrozole has not been studied in patients with severe hepatic impairment. The potential risk/benefit to such patients should be carefully considered before administration of anastrozole.</p><p><strong>Renal Insufficiency: </strong>Anastrozole pharmacokinetics have been investigated in subjects with renal insufficiency. Anastrozole renal clearance decreased proportionately with creatinine clearance and was approximately 50% lower in volunteers with severe renal impairment (creatinine clearance less than 30 mL/min/1.73m2&nbsp;or 0.5 mL/sec/1.73m2) compared to controls.</p><p>Because renal clearance is not a significant pathway of elimination, the apparent oral clearance of anastrozole is unchanged even in severe renal impairment. Dosage adjustment in patients with renal dysfunction is not necessary. The potential risk/benefit to patients with severe renal impairment should still be considered prior to the administration of anastrozole in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The majority of mice dosed orally with 250 mg/kg anastrozole and all mice dosed intraperitonealy with 50 mg/kg showed signs of non-specific toxicity following dosing, but all recovered by day 2 and appeared normal for the remainder of the 14 day observation periods. Rats did not tolerate doses of 250 mg/kg and above by either route. No atypical signs were seen in rats following 100 mg/kg orally. However, there were signs of non-specific toxicity, but no deaths, following 50 mg/kg intraperitonealy. Non-specific toxicity in the rodent comprised the following: subdued behaviour, hunched posture, trembling, decreased respiration rate, fully or partially closed eyes, pilo-erection, salivation, lacrimation, convulsions, loss of skin tone, and lying prone.</p><p>In dogs treated orally with 45 mg/kg anastrozole, only minimally toxic effects were observed consisting of emesis, loose stools, body weight loss and reduced food consumption.</p><p>&nbsp;</p><p><strong>Multiple Dose Toxicity Studies</strong></p><p>Anastrozole was well tolerated at up to 50 mg/kg/day in multiple dosing studies in rats, but 12 mg/kg/day was not tolerated in dogs in the 1 month study. Consequently, the top dose in the 6 month dog study was set at 8 mg/kg/day.</p><p>Anastrozole is a potent inhibitor of the aromatase enzyme and as such may be expected to induce a variety of effects resulting from the long-term inhibition of estrogen production in multiple dosing studies. Such pharmacological effects were observed in the reproductive tract and endocrine organs at all dose levels in rat and dog in both 1 month and 6 month toxicity studies. These effects included increased ovarian weight with increased numbers of Graafian follicles and/or corpora lutea together with mammary gland/uterine/vaginal changes in rats and dogs and testicular Leydig cell changes in dogs. Other pharmacologically induced changes in rats were reduced pituitary and adrenal gland weights, while in dogs, thymic involution was seen in both sexes in all dose groups. Changes in blood parameters included reversible increases in platelet numbers in both species, a reversible increase in erythrocyte parameters in female rats at 1 month, with a reversible decrease in male rats and dogs at 6 months, and increased white blood cells in rats of both sexes.</p><p>Non-pharmacologically induced changes in rats included an increased incidence of chronic progressive glomerular nephropathy at high dose (50 mg/kg/day) in the 6 month study. This was of minimal to mild severity and is thought to represent an exacerbation of the spontaneously occurring condition, possibly due to a slightly increased protein load in these animals. In addition, liver enlargement (reversible on withdrawal) accompanied by centrilobular hypertrophy and reduced glycogen at doses of 5 mg/kg/day and above in both the 1 month and 6 month studies, was considered indicative of induction of mixed function oxidases by anastrozole.</p><p>In the dog, liver enlargement (reversible on withdrawal), generally accompanied by centrilobular hypertrophy and increased plasma alkaline phosphatase, was seen at mid and high dose levels in both multiple dose toxicity studies. This finding was consistent with induction of mixed function oxidase enzymes. Reversible hepatotoxicity, characterised by multifocal degeneration/necrosis and accompanied by elevated plasma alanine aminotransferase, was seen at the high dose (8 mg/kg/day) in the 6 month dog study. No degenerative changes were seen at the mid dose (3 mg/kg/day) in dogs, implying at least a 150 fold margin for hepatotoxicity in the dog based on a human dosage of 1 mg/day (approximately 0.02 mg/kg and approximately a 40 fold margin based on comparable AUC data).</p><p>Changes in clinical chemistry parameters in the toxicology studies included a reduction in triglycerides (all doses) and an increase in cholesterol (5 and 25 mg/kg/day) in male rats after 1 month dosing, and changes in potassium levels at 25 mg/kg/day. In dogs, plasma cholesterol and urinary creatine were reduced after 1 month at 12 mg/kg/day. Cholesterol was increased in female dogs (no change in males) after 6 months at 8 mg/kg/day. However, no ocular effects were seen in either species.</p><p>A reversible reduction in R-wave amplitude was seen in the dog studies at the high doses of 12 and 8 mg/kg/day in the 1 and 6 month studies respectively. This effect was not accompanied by any waveform interval or histopathological changes and is of unknown etiology.</p><p>&nbsp;</p><p><strong>Reproductive Toxicology</strong></p><p>Anastrozole has been found to cross the placenta following oral administration of 0.1 mg/kg in rats and rabbits. Studies in both rats and rabbits at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively, administered during the period of organogenesis showed that anastrozole increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption and decreased numbers of live fetuses). Effects were dose related in rats. Placental weights were significantly increased in rats at doses of 0.1 mg/kg/day or more.</p><p>Evidence of fetotoxicity, including delayed fetal development (i.e. incomplete ossification and depressed fetal body weights), was observed in rats administered doses of 1 mg/kg/day. There was no evidence of teratogenicity in rats administered doses up to 1 mg/kg/day. In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1 mg/kg/day. There was no evidence of teratogenicity in rabbits administered 0.2 mg/kg/day.</p><p>Oral administration of anastrozole to female rats produced a high incidence of infertility at 1 mg/kg/day and increased pre-implantation loss at 0.02 mg/kg/day. These effects were related to the pharmacology of the compound and were completely reversed after a 5-week compound withdrawal period.</p><p>&nbsp;</p><p><strong>Oncogenicity</strong></p><p>The oncogenicity study in rats at doses of 1.0 to 25 mg/kg/day, administered by oral gavage for up to 2 years, revealed increases in the incidence of hepatocellular adenoma and carcinoma in high dose females, uterine stromal polyps in the high dose females and thyroid adenoma in the high dose males. Dose related increases were observed in the incidences of ovarian and uterine hyperplasia in females. At 25 mg/kg/day, plasma AUC(0-24hr) levels in rats were about 100 times higher than the level exhibited in postmenopausal volunteers at the recommended dose.</p><p>A separate oncogenicity study in mice at oral doses of 5 to 50 mg/kg/day for up to 2 years, produced increases in the incidence of benign ovarian epithelial and sex cord stromal granulosa cell tumours, at all dose levels. A dose related increase in the incidence of ovarian stromal hyperplasia was also observed in female mice. These ovarian changes are considered to be rodent-specific effects of aromatase inhibition and are of no significance to postmenopausal breast cancer patients. The incidence of lymphosarcoma was marginally increased in males and females at the high dose. At 50 mg/kg/day, plasma AUC(0-t) levels in mice were about 30 times higher than the level exhibited in postmenopausal volunteers at the recommended dose.</p><p>&nbsp;</p><p><strong>Other Toxicology Studies</strong></p><p>There were no significant findings in genetic toxicology or in special toxicity studies designed to assess the irritant or antigenic potential of anastrozole.</p><p>Additional studies to provide further reassurance of the mechanisms underlying the formation of liver and thyroid tumours in rats have been completed.</p><p>In the first study, female rats dosed with anastrozole at 25 mg/kg/day for up to 28 days showed a 27% increase in relative liver weight, an increase in hepatocyte replication, and centrilobular hepatocyte hypertrophy. It was concluded that anastrozole, a known hepatic cytochrome P450&nbsp;enzyme inducer in rats, elicited a spectrum of biological changes in the rat liver similar to those observed with the non-genotoxic hepatocarcinogen, phenobarbitone. The hepatic changes in this study, and the tumours seen in female rats at 25 mg/kg/day after two-years, are considered a result of this non-genotoxic process.</p><p>In the second study, male rats were dosed at 25 mg/kg/day for 30 days. Thyroid follicular epithelial cell hypertrophy, increased TSH activity and increased plasma clearance of 125I-T4, in association with liver enlargement, centrilobular hepatocyte hypertrophy, increase in CYP2B (predominantly) activity and increase in T4 UDP-glucuronyltransferase activity, are consistent with anastrozole being a liver enzyme inducer of the phenobarbitone type. Thus, the thyroid tumours that occurred in male rats dosed with 25 mg/kg/day anastrozole over two years can be considered to be mechanistically related to an increased clearance of thyroid hormone resulting from an induction of specific liver enzymes resulting in a TSH-mediated non-genotoxic response.</p><p>The spectrum of biological changes in the rat liver and thyroid are similar to those reported in the literature following the administration of the non-genotoxic carcinogen, phenobarbitone. It is, therefore, concluded that the hepatic and thyroid changes seen in these investigative studies confirm the non-genotoxic mechanism responsible for the formation of tumours in the two-year rat oncogenicity study. The results do not alter the risk benefit assessment for the clinical use of anastrozole.</p><p>In support of clinical investigations using the combination of anastrozole and tamoxifen, an investigative study was performed in the rat to determine whether anastrozole, when administered in combination with tamoxifen, alters the metabolism of tamoxifen and the level of tamoxifen-DNA adducts in the rat liver. In the high dose group, where anastrozole produced a major increase in liver P450 enzyme activity (specifically CYP2B and CYP3A), there was a significant reduction in the number of tamoxifen-DNA liver adducts compared to the animals given tamoxifen alone or in combination with a noninducing dose of anastrozole. The plasma concentration of anastrozole was not determined but, in combination with the high dose of anastrozole, there was a reduction in the concentration of tamoxifen in plasma and liver, and a reduction in the concentration of tamoxifen metabolites in the liver.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;Component</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Ref</strong><strong> </strong><strong>to Quality Standard</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;Function</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Quantity</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>% w/w</strong></p></td><td style="vertical-align:top"><p><strong>mg/tablet</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Core</strong></p></td></tr><tr><td style="vertical-align:top"><p>Anastrozole</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Active</p></td><td style="vertical-align:top"><p>1.087</p></td><td style="vertical-align:top"><p>1.000</p></td></tr><tr><td style="vertical-align:top"><p>Anhydrous Lactose</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Diluent/Filler</p></td><td style="vertical-align:top"><p>65.21</p></td><td style="vertical-align:top"><p>60.0</p></td></tr><tr><td style="vertical-align:top"><p>Microcrystalline Cellulose PH 102</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Binder/Filler</p></td><td style="vertical-align:top"><p>23.7</p></td><td style="vertical-align:top"><p>21.80</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose Sodium</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Disintegrant</p></td><td style="vertical-align:top"><p>6.96</p></td><td style="vertical-align:top"><p>6.40</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate ($)</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Lubricant</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>0.800</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Total</strong><strong> </strong><strong>Core</strong><strong> Tablet Weight</strong></p></td><td style="vertical-align:top"><p><strong>97.83</strong></p></td><td style="vertical-align:top"><p><strong>90.0</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Film-Coating</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methylcellulose 2910 E5</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Film forming polymer</p></td><td style="vertical-align:top"><p>0.815</p></td><td style="vertical-align:top"><p>0.750</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Cellulose Type LF</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Film forming polymer</p></td><td style="vertical-align:top"><p>0.272</p></td><td style="vertical-align:top"><p>0.250</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene Glycol 8000</p></td><td style="vertical-align:top"><p>NF</p></td><td style="vertical-align:top"><p>Plasticizer</p></td><td style="vertical-align:top"><p>0.543</p></td><td style="vertical-align:top"><p>0.500</p></td></tr><tr><td style="vertical-align:top"><p>Titanium Dioxide</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Opacifier</p></td><td style="vertical-align:top"><p>0.543</p></td><td style="vertical-align:top"><p>0.500</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water*</p></td><td style="vertical-align:top"><p>USP</p></td><td style="vertical-align:top"><p>Solvent</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>18.0</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Total</strong><strong> </strong><strong>Solids</strong><strong> </strong><strong>(excluding</strong><strong> </strong><strong>water)</strong></p></td><td style="vertical-align:top"><p><strong>2.17</strong></p></td><td style="vertical-align:top"><p><strong>2.0</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Total</strong><strong> </strong><strong>Film</strong><strong> </strong><strong>Coated</strong><strong> </strong><strong>Tablet </strong><strong>Weight</strong><strong> </strong><strong>(excluding</strong><strong> </strong><strong>water)</strong></p></td><td style="vertical-align:top"><p><strong>100.0</strong></p></td><td style="vertical-align:top"><p><strong>92.0</strong></p></td></tr></tbody></table><p>($) The quantity of magnesium stearate NF is adjusted based on the actual amount of compacted material.</p><p>*Evaporates during the coating process. Does not contribute to the total weight of tablet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>N/A</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C. Protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>30&#39;s</p></td><td style="vertical-align:top"><p>Bottle</p></td><td style="vertical-align:top"><p>Bottle: BOT 100 CC OPQ WHT HDPE SQR</p><p>Cap: Cap PP 38MM-400 BLUE CR</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special precautions are needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Incorporated 
150 Signet Drive
Toronto, Ontario 
Canada, M9L 1T9
Tel: 1-800-268-4623, Fax: 1-800-609-9444
www.apotex.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>